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Abstract

GENETIC AND EPIGENETIC MECHANISMS OF COMPLEX REPRODUCTIVE
DISORDERS
By, Bhavi P. Modi, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Major Director: Jerome F. Strauss III, M.D., Ph.D.
Dean of the School of Medicine
Professor, Dept. of Obstetrics and Gynecology; Dept. of Human and Molecular Genetics

Common, complex disorders are usually polygenic, heterogeneous and multifactorial
traits representing interactions between environmental, genetic and epigenetic factors.
Next generation genomic technologies have uncovered risk factors for several complex
traits. More often than not, contributions of these risk factors have been studied
individually. The application of these technologies to the study of complex female
reproductive traits has been challenging. This thesis explores the potential of genetic
and

epigenetic

components

contributing

x

to

a

better

understanding

of

the

biological pathways underlying disease risk in two specific female complex reproductive
traits - polycystic ovary syndrome (PCOS) and preterm premature rupture of
membranes (PPROM). After introducing the clinical context and the genetic architecture
for each disorder, I describe individual projects that together aim at understanding the
genetic and epigenetic regulation of genes associated with disease susceptibility. The
PCOS projects focus on characterization of a gene, DENND1A, whose association to
PCOS was first established by Genome Wide Association Studies (GWAS) and one of
its isoforms – DENND1A.V2, is known to functionally contribute to the PCOS pathology
via increased androgen production. This study showed that decreased miR-125a-3p
expression is correlated to increased DENND1A.V2 and increased DHEA accumulation
in PCOS theca cells. A common network of differentially regulated miRNAs identified in
this study and known PCOS candidate loci was also identified. The studies on PPROM
utilize a Whole Exome Sequencing approach to identify rare variants in fetal genes
contributing to extracellular matrix composition and synthesis contributing to PPROM
risk. The results suggest that fetal contribution to PPROM is polygenic and is driven by
a significant genetic burden of potentially damaging rare variants in genes contributing
to fetal membrane strength and integrity. Tissue and location specific expression
patterns of the Chromosome 21 miRNA cluster (miR-99a, miR-125b, let-7c) in fetal
membranes from term pregnancies with spontaneous rupture were investigated. Unique
expression profiles for all three miRNAs between the rupture and non-rupture sites were
identified. The miRNAs were also differentially expressed between trisomy 21 (T21) and
euploid control amniocyte cultures. The results suggest that these miRNAs play

xi

potential roles in fetal membrane rupture and fetal membrane defects associated with
T21.
Keywords: Polycystic Ovary Syndrome, DENND1A, Preterm Premature Rupture of
Membranes, microRNA.
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Chapter 1: Introduction and Background

1.1. Introduction
The genetic architecture of complex genetic disorders is represented by interactions
between environmental, genetic and epigenetic factors. In contrast with single gene
Mendelian disorders, single genetic variants are insufficient to cause complex genetic
disorders. Instead, multiple variants of low penetrance at multiple loci act synergistically
to contribute to complex disease risk. While environmental factors can be modified, the
genetic factors predisposing to disease risk remain stable and need to be determined.
The approaches used to study complex disease genetics have evolved rapidly with the
development of new genomic technologies – from family-based studies and linkage
analysis, twin studies, candidate-gene studies, to population-based techniques using
microarray and next-generation sequencing approaches such as Genome Wide
Association Studies (GWAS) and Whole Exome Sequencing (WES) (1,2).
Genetic contributions to female reproductive disorders and pregnancy complications
have been established but the precise genetic etiology contributing to disease
mechanism is not yet completely understood. These disorders typically manifest as
heterogeneous and complex traits resulting from multiple genetic and environmental
factors (3). The progress of genetic studies in these disorders has been slow as
compared to other complex genetic disorders such as schizophrenia (4) and coronary
artery disease (5). This thesis describes the studies designed and performed
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to understand the genetic and epigenetic mechanisms of complex reproductive
disorders, with specific focus on polycystic ovary syndrome (PCOS) and preterm
premature rupture of membranes (PPROM).
Demonstrating direct causation in any complex genetic trait is almost always
impossible, and as discussed in the sections below, it is even more challenging for
disorders of female reproduction. The research approaches utilized to identify genetic
variants should be aimed at gaining evidence that variants at least show a consistent
correlation with gene expression or gene regulation that is highly correlated with the
human trait originally assayed (6). Together, the two models present opportunities to
study complex disease genetics using three broad approaches. The studies on PCOS
(Chapter 2) essentially focus on the characterization of a trait (PCOS) - associated
locus originally identified by GWAS, but whose association to PCOS has been securely
implicated. The studies on PPROM (Chapter 4) utilize a WES approach to identify rare
variants contributing to PPROM risk, focusing on variant prioritization for replication and
follow up in genes with biological relevance to PPROM. In addition the role of miRNAs
in epigenetic mechanisms of gene regulation in both PCOS (Chapter 3) and PPROM
(Chapter 5) is investigated.
The following sections describe the clinical overview, genetic architecture and the
ongoing research and its limitations in both PCOS and PPROM followed by a brief
chapter-wise thesis outline.
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1.2. PCOS background
1.2.1. Clinical Overview of PCOS
PCOS is a common reproductive endocrinological disorder that affects 5% - 15%
women of reproductive age and is the leading cause of female infertility worldwide (7,8).
It is a multisystem, heterogeneous disorder characterized by a broad spectrum of
reproductive, metabolic and endocrinological features. The typical ovarian morphology,
which gives the disorder its name, consists of multiple, small, subcortical follicular cysts
in bilaterally enlarged ovaries. (Figure 1.1) Other features include irregular periods
(oligo/ amenorrhea), oligo/ anovulation, infertility, hyperandrogenism, hirsutism, acne,
insulin resistance and weight-gain (9). PCOS women have higher prevalence rates of
cardiovascular disease, Type 2 Diabetes Mellitus (T2DM) and metabolic syndrome,
irrespective of their age and body mass index (10,11).
PCOS is one of the most ill-defined endocrinological conditions with considerably
debated diagnosis schemes and varying prevalence rates based on the diagnostic
criteria applied (7). Three different classification systems have been used for PCOS
diagnosis over the years – the National Institutes of Health (NIH) criteria (12), the
Rotterdam criteria (13), and the Androgen Excess and PCOS Society criteria (14)
(Figure 1.2). This shows that the existing diagnostic criteria are based on expert
consensus of clinical findings as opposed to strong molecular evidence and these are
limited to reproductive-aged women. Several symptoms, especially reproductive and
some endocrine features improve over time, however associated metabolic dysfunction
persists throughout a woman’s lifetime further adding to risk for cardiovascular disease.
Recently, the use of serum Anti-Mullerian hormone (AMH) levels as a biomarker for
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PCOS diagnosis has been considered (15,16). In addition, none of these criteria include
other endocrinopathies and metabolic features that are commonly observed in PCOS
patients such as abnormal glucose metabolism, insulin resistance, dyslipidemia, weight
gain and obesity. Development of molecular diagnostic techniques for PCOS will aid in
early diagnosis in adolescents and pre-pubertal girls as opposed to late symptomatic
diagnosis or more invasive procedures such as trans-vaginal ultrasound, and this can
help prevent complications through lifestyle choices when possible for e.g. by controlling
diet, exercise etc. Thus, accurate and early diagnosis of PCOS is essential not only to
prevent potentially life-long associated comorbidities, but to also reduce the healthcare
related economic burden of PCOS. The US health care system spends around 4 billion
dollars annually in diagnosis and treatment of the primary PCOS symptoms as well as
associated morbidities in pre-menopausal women (17). The hidden costs of life-long
sequelae resulting from a PCOS background are difficult to estimate. It is also important
to note that male and female first-degree relatives of women with PCOS have increased
risk

of

developing

associated

metabolic

and

endocrine

conditions

including

hyperandrogenism, obesity, insulin-resistance and T2DM (18,19). This underlines the
genetic complexity of PCOS and further stresses the need to identify candidate genes.
Most consensus diagnostic schemes recommend the presence of hyperandrogenism
(clinical or biochemical) a must for concluding a PCOS diagnosis. A cross-sectional
case-control study suggested that hyperandrogenism is implicated in both the metabolic
and reproductive morbidities of PCOS and maybe a common link between the two
(9,20). Ovarian androgen production is increased in PCOS and studies show that
ovarian theca cells from PCOS women secrete more androgen than theca from
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regularly ovulating women (21,22). Thus, hyperandrogenism is considered to be the
hallmark of PCOS, which is directly or indirectly, linked to several other PCOS
symptoms and is central to understanding PCOS etiology.
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Figure 1.1. Normal vs. Polycystic Ovary: Normal ovulation follows a sequential series
of developmental events in the follicles resulting in release of mature egg (ovulation). In
a polycystic ovary, follicular development is arrested, resulting in accumulation of
multiple immature follicles (< 10 mm), which overtime, appear as multiple small,
subcortical follicular cysts.
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Rotterdam
Convention
(2003)
(any 2 of 3)

NIH Consensus
De6inition
(1990)

Hyperandrogenism

Hyperandrogenism
(Clinical/
Biochemical)

Androgen
Excess and
PCOS Society
(2006)
Hirsutism and/ or
hyperandrogenism
(Required)

Oligo- and/ or
Anovulation

Anovulation

Polycystic Ovaries on
Ultrasound

Oligo-ovulation
and/ or
Polycystic Ovaries

Figure 1.2: PCOS diagnostic criteria. Three commonly used PCOS diagnostic criteria
are described. A PCOS diagnosis requires the exclusion of other diseases that may
contribute to these clinical criteria used including 21-hydroxylase deficiency, Cushing’s
syndrome, and hyperprolactinemia.
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1.2.2. Genetic architecture of PCOS
Initial evidence for genetic predisposition in PCOS was based on familial clustering of
cases (23). The disorder was first thought to follow an autosomal dominant mode of
inheritance with variable penetrance (8). Association and linkage studies and numerous
candidate gene studies, though largely unsuccessful in yielding statistically significant
and replicable results, provided evidence that a number of genes are differentially
expressed in PCOS, which lend support to a polygenic mode of inheritance as opposed
to a single-gene Mendelian model. Now, it is well established that PCOS is a complex
genetic disorder with multiple genetic and environmental factors interacting and
contributing to disease pathology (24,25). Twin studies and family-based association
studies carried out on a Dutch population including more than 1300 monozygotic twins
and 1800 dizygotic twins/ singleton sisters of twins showed that genetic factors account
for ~70% of heritability in PCOS (26). The clinical features used for PCOS diagnosis,
including polycystic ovaries, hyperandrogenism as well as oligo-amenorrhea have
hereditary components with characteristics suggestive of an autosomal dominant trait
(26–29). Hyperandrogenism is shown to be the strongest heritable characteristic in
families with multiple PCOS patients (24,30). Other features commonly found in
association with PCOS including metabolic syndrome, T2DM and obesity are also
heritable characteristics (10,31,32). Environmental factors that may contribute include
intra-uterine factors such as prenatal nutrition and/ or androgen exposure, while major
postnatal factors are related to a person’s lifestyle such as diet, exercise, abdominal fat
and body mass index (8).
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The genetic architecture of PCOS has been summarized by Rosenfield et al (8) – “At its
simplest, this is a “two-hit” hypothesis that can be thought of because of a congenitally
programmed predisposition (“first hit”) that becomes manifest upon exposure to a
provocative environmental factor (“second hit”)”. The congenital “hit” consists mostly of
genetic variants affecting hyperandrogenism or ovarian function but can also be
acquired factors such as intra-uterine nutrition or androgen exposure in utero. The
provocative “hits” are postnatal factors including obesity and insulin resistance that may
be caused by T2DM related gene variants.

1.2.3. DENND1A: From GWAS to molecular mechanisms
Candidate gene association studies in PCOS were primarily focused on genes involved in
folliculogenesis, steroidogenesis, insulin production and function. Owing to small sample
sizes and resulting limited statistical power, most of them failed to yield statistically significant
results that could be replicated (24,25,33). The first successful GWAS in PCOS was
published in 2011 on a Han-Chinese population with a follow-up GWAS published in 2012
(34,35). Subsequent GWAS on European populations have confirmed associations of some
(as shown in Table 1.1) of the variants identified in the Han-Chinese GWAS to PCOS, and
also identified additional candidate loci (36,37). Together, the four GWA studies have
identified 22 candidate loci for PCOS (Table 1.1). Interestingly, association of the DENND1A
gene locus (Chromosome 9: 9p33.3) to PCOS has been consistently replicated in several
studies (38–40). In addition, association to related phenotypes including elevated serum
glucose levels, insulin levels and body weight has been documented (41).
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As described in greater detail in chapter 2 studies in theca cells from normal cycling women
and women with PCOS provide evidence for functional association of increased expression
of an alternatively spliced isoform of the DENND1A gene - DENND1A.V2 (V2) to PCOS.
While showing potential for V2 to be utilized as a diagnostic and therapeutic target, this study
does not determine the mechanisms of V2 overexpression in PCOS theca cells (42). The
DENND1A SNPs (single nucleotide polymorphisms) - identified in Han Chinese GWAS –
rs10818854, rs2479106, rs10986105 - are located in the intronic regions of the gene (34,35).
The DENND1A signal reported (suggestive locus – rs10760321) in European population is
intergenic and was not confirmed in follow-up samples (37).
The genetic mechanisms contributing to V2 overexpression need to be studied. Moreover,
the reported odds ratios of association of the gene with PCOS are low to modest, which
suggests variations in DENND1A and the resultant functional consequences of V2
overexpression alone cannot explain the heritability of PCOS. Considering PCOS is a
polygenic disorder and the known functional significance of DENND1A in PCOS etiology, it is
more likely that other genes, possibly in a common network with DENND1A contribute to
PCOS pathophysiology.
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Table 1.1. PCOS risk loci reported to date. Genetic variants associated with PCOS risk
identified in Han Chinese (CHN) and European (EUR) populations are described.

Discovery
p-value

Discovery
population

Ref

rs2268361

Risk/
Other
allele
T/C

9.89 x 10-13

CHN

35

rs2349415
rs13405728
rs13429458
rs12478601
rs12468394
rs7563201
rs1351592
rs13164856
rs804279
rs4385527

T/C
G/A
C/A
T/C
A/C
G/A
G/C
T/C
A/T
A/G

2.35 x 10-12
7.55 x 10-21
1.73 x 10-23
3.48 x 10-23
1.59 x 10-20
3.3 x 10-10
1.2 x 10-12
3.5 x 10-9
8 x 10-10
5.87 x 10-9

CHN
CHN
CHN
CHN
CHN
EUR
EUR
EUR
EUR
CHN

35
34
34
34
34
36
36
36
37
35

C9orf3

rs3802457

A/G

5.28 x 10-14

CHN

35

C/T
G/A
A/G
C/A

4.6 x 10-13

DENND1A

rs10993397
rs2479106
rs10818854
rs10986105

8.12 x 10-19
9.4 x 10-18
6.9 x 10-15

EUR
CHN
CHN
CHN

37
34
34
34

rs10760321
rs11031006
rs1894116

A/G
G/A
G/A

1.4 x 10-6
1.9 x 10-8
1.08 x 10-22

EUR
EUR
CHN

36
37
35

rs11225154
rs705702
rs7312770
rs2272046
rs1275468
rs4784165
rs7218361
rs2059807

A/G
G/A
C/T
C/A
C/T
G/ T
A/G
G/A

7.6 x 10-11
8.64 x 10-26
2.1 x 10-7
1.95 x 10-21
1.9 x 10-8
3.64 x 10-11
9.6 x 10-7
1.09 x 10-8

EUR
CHN
EUR
CHN
EUR
CHN
EUR
CHN

36
35
36
35
24
35
36
35

rs6022786

A/G

1.83 x 10-9

CHN

35

Locus

Gene

2p16.3

FSHR

2p16.3

LHCGR

2p21

THADA

2q34
5q31.1
8p23.1

ERBB4
RAD50
GATA4/NEIL2

9q22.32

9q33.3

11p14.1

KCNA4/FSHB

11q22.1

YAP1

12q13.2
12q13.2
12q14.3
12q21.2
16q12.1
17q12
19p13.2

RAB5B/SUOX
ERBB3
HMGA2
KRR1
TOX3
ERBB2
INSR
SUMO1P1/
ZNF217

20q13.2

GWAS Index
SNP
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1.3. PPROM Background
1.3.1. Clinical Overview of PPROM
In humans, the normal term gestational period for singleton pregnancies is 37 – 41
weeks, with gestational age determined from the first day of the last menstrual period or
early second trimester estimation for confirming gestational age (43). Maternal and fetal
physiological changes at term promote uterine contractions and breakdown of fetal
membranes (amnion and chorion) to facilitate parturition. Variety of factors can
contribute to early initiation or changes in these pathways resulting in preterm birth
(PTB), which is defined as birth prior to 37 weeks of gestation. PTB is the leading cause
of neonatal mortality and infant morbidity occurring in ~12% of all pregnancies in the
United States (44,45). Children who are born preterm have increased risks of several
short and long-term health sequelae owing to systemic immaturity. Immediate health
complications

include

respiratory

distress

(due

to

poorly

developed

lungs),

intraventricular hemorrhage, jaundice, anemia and infection. Long-term health impacts
can include intellectual and developmental disabilities, cerebral palsy, lung problems,
vision and hearing loss. In addition, children who are born preterm also have an
increased risk of adult-onset diseases such as obesity, diabetes and hypertension
(www.marchofdimes.com/prematurebabies).

Despite

the

advances

in

research,

healthcare and increasing knowledge of risk factors leading to PTB, the rate of PTB in
US has not decreased in the last few decades (46,47).
There are two major proximate causes for PTB – spontaneous PTB (sPTB) with intact
membranes and preterm premature rupture of membranes (PPROM). Preterm
premature rupture of membranes (PPROM) is characterized by rupture of the fetal
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membranes prior to the onset of labor before 37 weeks of gestation. It occurs in 2% 3% of all pregnancies and accounts for approximately 40% of all PTBs (48). PPROM
occurs at higher frequencies among African-American women compared to other
populations in the US and these population-specific disparities cannot be explained by
socio-economic factors. Genetic variation and therefore gene-environment interactions
are thought to be involved (49,50).
Diagnosis of PPROM is made based on visual pooling of clear amniotic fluid in the
cervix, confirmation of alkaline pH of the cervicovaginal discharge (amniotic fluid) which
is typically done using a nitrazine (pH indicator) test and/ or a fern test, which is
microscopic observation of ferning patterns of amniotic fluid on drying. Using these
clinical signs have limitations in terms of accuracy as most of these tests become less
accurate more than 1 hour after membrane rupture (51).
Understanding the genetic factors contributing to PPROM risk can help us identify early
on in pregnancy, which women have an increased risk for PPROM. This can help
identify the healthcare management options to prevent PPROM (by controlling other risk
factors) and to assure best possible perinatal outcomes.

1.3.2. Genetic Architecture of PTB/ PPROM
Genetic contribution to PTB was initially widely debated with suggestions that variations
in PTB risk including population-specific differences can be attributed to socioeconomic
(education, access to healthcare), behavioral (smoking, alcohol and drug use), and
environmental factors (stress). However, more studies demonstrated that these factors
do not completely account for the risk of PTB in families and even after controlling for
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these factors, PTB risk (specifically PPROM) is greater among African-Americans
(49,50). This indicated that genetic factors likely contribute to PTB risk. Supporting this
were reports indicating increased frequency of PTB in mothers with prior history of PTB
and correlations observed between mother-daughter, sister-sister relationships within
the same families. This is true even for PPROM. (52,53). These correlation patterns can
be explained by both genetic as well as environmental factors shared within families
and indicate that PTB and its specific sub-phenotype PPROM are complex genetic
disorders. However, determining the genetic architecture is difficult because in addition
to the heterogeneous, multifactorial, complex genetic nature of the disorder, the
involvement of not one, but two genomes has to be considered – maternal and fetal.
The contribution of fetal genetic factors have been estimated to range from 11 – 35%,
whereas the contribution of maternal genetic factors is in the range of 13 – 20% (54).
Gene x environment interactions are considerably more challenging to understand in
PTB as compared to other complex genetic disorders due to the interaction between the
in utero environmental effects of the maternal genotype and the developmental effect of
the fetal genotype.
Environmental factors contributing to PTB risk include familial sources of variation that
would, in theory, affect all births of the same mother such as socioeconomic status,
stress, smoking, congenital maternal health problems, and also those environmental
factors that are unique to individual pregnancies such as infections (Figure 1.3).
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Gene$cs of PPROM
Maternal Gene*cs
Maternal Environment
(e.g. infec$on, stress,
smoking, substance abuse)

Untransmi4ed
Transmi4ed

Birth
Timing
Maternal

Fetal Environment
(in utero condi$ons)

Paternal
Fetal Gene*cs

Figure 1.3. Genetic Architecture of Birth Timing. The complex genetic architecture of
PPROM is influenced by both maternal and genetic factors. Maternal genetic factors
influence the fetal genetic factors as well as the fetal environment in utero. In addition,
gene x environment interactions exist between maternal genetic factors and general
maternal environment such as nutrition status, smoking and substance abuse and
pregnancy specific maternal environment such as acquired infections during pregnancy.
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1.3.3. Rare Variant Analysis in fetal collagen genes contributing to PPROM risk
GWAS has had very limited success in identifying loci associated to PTB. Identified loci
lose significance after testing for multiple corrections or are not reproducible in follow up
studies. This can be attributed to several limitations in study design such as limited
sample size, inadequate power, population heterogeneity and variations in definitions of
PTB including the proximate cause of PTB used for each study, which makes replication
of results more difficult. (46,55,56). It is important to recognize that different subphenotypes of PTB (sPTB or PPROM) may result from different pathways, and can
even have varying contributions of participating genomes (maternal vs. fetal) towards
the genetic risk. The poor outcome from standard genetic approaches used to study
PTB suggests that other methods need to be utilized to identify the genetic contribution
to PTB. There have been no PTB GWAS focusing specifically on PPROM as the
etiology leading to PTB. The majority of studies have focused on candidate genes in the
maternal genome involved in inflammatory pathways such as Tumor Necrosis Factoralpha (TNFA), Toll-like receptor 4 (TLR4) and Caspase Recruiting Domain protein - 15
(CARD15) (57,58). Despite evidence of fetal contribution to PPROM established by twin
studies, not many studies have investigated variations in fetal genes contributing to
PPROM (54,59). As suggested earlier, the pathways and genomes contributing to
PPROM can be vastly different to those contributing to sPTB. This also has been
suggested in a recent study investigating the pathway analysis of genetic factors
associated with the two PTB subtypes (60). Moreover, all studies on PTB in general
have focused on identifying common variants contributing to preterm birth risk. A study
of rare variants contributing to birth timing has not been performed. As described in
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Chapter 4, this thesis describes a unique approach towards identification of rare
variants in the fetal genome in select genes that are known to contribute to fetal
membrane structure and integrity.

1.4. MicroRNA regulation in PCOS and PPROM
GWAS and WES are approaches used to investigate alterations within the DNA
sequence (common and/ or rare variants) contributing to disease association or disease
risk. In contrast, epigenetic approaches are used in the study of complex genetic
diseases to investigate heritable gene expression changes that occur without alterations
of the underlying DNA sequences and contribute to disease mechanisms. Commonly
studied epigenetic changes include DNA modifications such as methylation and histone
modifications.
MiRNAs are small (20 – 24 nucleotides), single-stranded, non-coding RNA molecules
involved in post-transcriptional regulation of gene expression via translation inhibition or
mRNA degradation (61,62). Since miRNAs induce gene expression changes without
altering underlying DNA sequences, they contribute to epigenetic mechanisms of gene
expression regulation. Normal ovarian function and normal parturition require a series of
closely coordinated events that require tightly controlled gene regulation. Several
investigators have studied and identified the role of miRNAs in regulating the normal
functioning of these pathways including folliculogenesis, androgen regulation,
contributing to preterm birth and preeclampsia (63–65). PCOS as well as PPROM are
perturbations of the normal ovarian and parturition or birth timing pathways and this led
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us to the hypothesis that differential miRNA expression patterns could contribute to the
epigenetic landscape of disease mechanisms for these two disorders.
In addition, the study of miRNAs in female reproductive disorders and adverse
pregnancy outcomes is especially exciting because of accessibility of miRNAs in the
serum, plasma, urine and saliva either as free circulating forms or encapsulated in
vesicles, making them excellent non-invasive diagnostic and prognostic biomarkers of
disease. This is particularly helpful in PCOS and PPROM where non-invasive
accessibility of disease relevant organs and tissues is difficult or impossible, making
diagnosis and following of disease progression extremely challenging.

1.5. Thesis Outline
Chapter 2 describes the genetic mechanisms for V2 overexpression in PCOS theca
cells via WES analysis, copy number variation assessment and analysis of genetic
variants in the intronic region where alternative splicing of DENND1A gene is thought to
occur to produce V2. None of these mechanisms provide concrete evidence of
contributing to V2 overexpression in PCOS, suggesting the potential role of miRNA
regulation.
In Chapter 3 the epigenetic mechanisms of miRNA contribution to PCOS etiology via
miRNA regulation are studied. Using miRNA deep sequencing, the study shows
evidence for differential microRNA expression in PCOS theca cells as compared to
unaffected control theca cells. It describes the potential role of miR-125a-3p in
regulating DENND1A.V2 gene expression and contributing to hyperandrogenism in the
PCOS theca.
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Chapter 4 describes a whole exome sequencing approach in African Americans to
identify rare genetic variants in fetal genes encoding fibrillar collagen and enzymes and
chaperone proteins involved in collagen synthesis contributing to increased risk for
PPROM. The findings suggest that the fetal contribution to PPROM is polygenic, and
driven by an increased burden of rare variants that may also contribute to the disparities
in rates of preterm birth among African Americans.
Chapter 5 investigates tissue and location specific expression patterns of three miRNAs
(miR-99a, miR-125b and let-7c) derived from Chromosome 21 in chorioamniotic
membranes from term pregnancies with spontaneous rupture. Results suggest the Chr
– 21 derived miRNAs play a potential role in fetal membrane rupture and fetal
membrane defects associated with Trisomy 21.
Chapter 6 discusses the connecting themes underlying the dissertation work in
Chapters 2 – 5 and comments on future directions.
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Chapter 2: Genetic mechanisms of DENND1A.V2 overexpression in PCOS theca
cells.
Please note: Part of the material in this chapter has been published in
i)

McAllister JM, Modi B, Miller BA, Biegler J, Bruggeman R, Legro RS, Strauss
JF 3rd. Overexpression of a DENND1A isoform produces a polycystic ovary
syndrome theca phenotype. Proc Natl Acad Sci USA. 2014; 111(15): E151927

ii)

Tee MK Speek M, Legeza B, Modi B, Teves ME, McAllister JM, Strauss JF
3rd, Miller WL. Alternative splicing of DENND1A, a PCOS candidate gene,
generates variant 2. Mol Cell Endocrinol. 2016; 434: 25 – 35

Abstract
Identification of DENND1A as a PCOS candidate gene in Han Chinese and European
Genome Wide Association Studies, replication in follow-up association studies and
evidence for overexpression of one of the isoforms – DENND1A.V2 (V2) - in PCOS
theca cells responsible for their steroidogenic phenotype, makes the gene the most
potential key factor in the molecular pathogenesis of PCOS. In order to completely
understand the functional significance of this gene and its contribution to PCOS, it is
first important to elucidate the exact mechanism by which V2 is produced and
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overexpressed in PCOS theca cells. The present study indicates that V2 is produced by
the exonization of intronic regions between exons 20 and 21 within the DENND1A gene.
In addition, genetic mechanisms including coding/ splice site variations, copy number
changes as well as intronic region variations were investigated and no evidence for their
contribution to overexpression of V2 in PCOS theca cells was found.
2.1. Introduction
Polycystic Ovary Syndrome (PCOS) affects 5% - 15% women of reproductive age
across different ethnicities (7,8). The disorder is associated with a typical ovarian
morphology of multiple, small, subcortical follicular cysts in bilaterally enlarged ovaries,
irregular periods (oligo/ amenorrhea), oligo/ anovulation, infertility, hyperandrogenism,
insulin resistance and weight-gain (9). It is a heterogeneous disorder with a strong
evidence for a genetic component, either autosomal dominant or oligogenic/ polygenic
(25,30).

Incomplete

penetrance,

epigenetic

modification,

and

environmental

contributions have hindered attempts to clarify the underlying mode of inheritance.
Numerous candidate gene association studies have been conducted, but few have
yielded statistically significant associations that have been replicated. Genome wide
association studies (GWAS) with large populations of Han Chinese individuals identified
eleven PCOS candidate loci, including DENND1A (34,35). Additional studies in
European populations confirmed the association of DENND1A with PCOS strongly
supporting DENND1A as a PCOS candidate gene (Chapter 1, Table 1.1) (36–40). In
addition, association to related phenotypes including elevated serum glucose levels,
insulin levels and body weight has been documented (41).
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The 18 human genes in the DENND family encode proteins that function as Rabspecific GTPases involved in membrane trafficking. The DENND1A gene consists of 22
exons and encodes the protein connecdenn 1, which has a clathrin-binding domain
thought to facilitate endocytosis (66). DENND1A yields two principal transcripts: variant
1 (V1), encodes a 1009 AA protein with three DENN (differentially expressed in normal
and neoplastic cells) domains and a C-terminal proline-rich domain; variant 2 (V2),
encodes a 559 AA protein that contains the three DENN domains, but lacks the prolinerich domain, and includes a C-terminal 33 AA sequence that differs from V1 (Figure
2.1). Recent work has directly implicated V2 in the pathophysiology of PCOS: V2 mRNA
and protein were overexpressed in PCOS theca cells compared to unaffected control
theca cells; over-expression of V2 in unaffected control theca cells increased the
abundance of cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17A1)
mRNA, augmented dehydroepiandrosterone (DHEA) production and increased the
activity of transfected CYP11A1 and CYP17A1 promoter-reporter constructs; and siRNA
knockdown of V2 in PCOS theca cells reversed the PCOS phenotype. In addition, V2
mRNA was abundant in urinary exosomes of PCOS women but not normally-cycling
women (42). These results suggest the diagnostic potential of V2. Especially, a
diagnostic method based on urine exosomal RNA would have a great potential as noninvasive and early diagnosis tool, which will be helpful for early detection in prepubertal
adolescent females (67). However, in order to completely understand the functional
significance of this gene and its contribution to PCOS and to better exploit its use as
potential diagnostic tool, it is important to elucidate the exact mechanism by which V2 is
produced and overexpressed in PCOS theca cells. The SNPs in DENND1A identified by
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GWAS are located in introns, and lack apparent functions that would favor splicing of V2
over V1.
As suggested previously overexpression of V2 in PCOS suggests the contribution of
gain-of-function variation (42). Thus, we sought to determine the mechanisms leading to
production of V2 and its overexpression in PCOS by testing several possible
mechanisms including examination of coding or splicing variants in the DENND1A gene,
investigation of copy number variations in the DENND1A gene and sequencing of the
intronic region that may explain alternative splicing of V1 and V2.
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Figure 2.1. The DENND1A gene.
The DENND1A gene is a member of a family of 18 genes, which encode for proteins
containing DENN domains: domains that are differentially expressed in normal and
neoplastic cells. DENND1A has a tripartite DENN domain consisting of upstream (uDENN), central / core DENN and a downstream (d-DENN) elements which are
separated by linker sequences. V1 encodes a full-length protein with 1009 amino acids
consisting of all three DENN domains, a clathrin-binding domain and a C-terminal
proline rich domain. V2 encodes a protein with 559 amino acids containing the three
DENN domains and the clathrin-binding domain (not shown in the figure but is present
downstream of the three DENN domains), but lacks the proline rich domain and has a
unique 33 AA sequence that is not present in the full-length protein.
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2.2. Materials and Methods
2.2.1. Unaffected and PCOS theca cells: Human theca interna tissue was obtained
from age-matched (38 – 40 years old), normal cycling women and women with PCOS
undergoing hysterectomy, following informed consent under a protocol approved by the
Institutional Review Board of The Pennsylvania State University College of Medicine, as
previously described (68). All oophorectomies were performed during the luteal phase.
The diagnosis of PCOS was made according to NIH consensus guidelines (9), which
include hyperandrogenemia, oligoovulation, polycystic ovaries, and the exclusion of 21hydroxylase deficiency, Cushing’s syndrome, and hyperprolactinemia. All of the PCOS
theca cell preparations studied came from ovaries of women with fewer than six menses
per year and elevated serum total testosterone or bioavailable testosterone levels (42).
Each of the PCOS ovaries contained multiple subcortical follicles of less than 10 mm in
diameter. The control (unaffected) theca cell preparations came from ovaries of fertile
women with normal menstrual histories, menstrual cycles of 21-35 days, and no clinical
signs of hyperandrogenism. Neither PCOS nor unaffected control subjects were
receiving hormonal medications at the time of surgery. Indications for surgery were
dysfunctional uterine bleeding, endometrial cancer, and/or pelvic pain.

Theca cells

were isolated and cultured as previously described (68). All experiments comparing
PCOS and unaffected control theca were performed utilizing 4th-passage theca cells
propagated from frozen stocks of second passage cells in media as described
previously (68). The passage conditions and split ratios for all control and PCOS cells
were identical.
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2.2.2. WES Analysis of Control and PCOS Theca Cell DNA. Unaffected control (n =
6) and PCOS (n = 6) genomic DNA samples were subjected to whole exome
sequencing at 100 millions reads, at 100X coverage using the Agilent SureSelect 51M
capture kit with Illumina HiSEq 2000 sequencing, in conjunction with BGI Americas.
Sequence reads obtained were aligned to the reference genome (Human hg19) by BGI
Americas. Variant calling and summary of data production was performed by BGI.
Visualization of data and identification of called variants was done using the IGV
(Integrative Genomic Viewer) software. Only those variants with IGV support numbers
>15 (count of the uniquely mapped base) for the alternative allele were selected from
the control unaffected and PCOS theca cell samples for further analysis. SNPs in
DENND1A were identified and their alternative allele frequencies were calculated.
2.2.3. CNV Analysis
From WES data: The reads obtained from WES were used to call for CNV using two
different platforms – Conifer and ExomeCNV, in conjunction with BGI Americas.
CNV Assessment using qPCR: Genomic DNA samples from unaffected (n = 6) and
PCOS (n = 8) theca cell cultures were all adjusted to a concentration of 5 ng/µl for CNV
qPCR assays. Quantitative PCR analysis was performed using commercially available,
predesigned TaqMan Copy Number Assays from Life Technologies targeting two
different regions in the DENND1A gene – i) overlapping exon 2 – intron 2 boundary and
ii) overlapping exon 20 – intron 20 boundary. RNAse P Copy Number Reference Assay
was used as the endogenous control. QPCR assay and analysis was performed in
quadruplicates following manufacturer’s protocols on an ABI 7900 HT Fast PCR
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System. The raw data obtained from the qPCR assay was analyzed by the maximum
likelihood method available in the Copy Caller v1.0 software (Applied Biosystems).
2.2.4. Genomic DNA Sequencing
Genomic DNA isolated from leukocytes (20 unaffected control and 20 PCOS) and theca
cell cultures (8 unaffected control and 8 PCOS) was prepared using the “Wizard”
genomic DNA purification kit (Promega), and initial direct sequencing was initiated with
primers S1280 and AS1670. The region encompassing exons 20 to 20A was amplified
using primers S1626 and AS3776 and the resulting 2.15 kb fragment was cloned into
pSC-A-amp/kan vector. Between 7 and 9 individual clones were selected from each
sample and sequenced with primers S1280 and AS1670. Original chromatograms were
visually inspected to identify double peaks.
2.2.5. Minigene construction and splicing analysis
Please note: minigene construction and splicing analysis were performed by Dr. Walter
Miller’s laboratory at the University of California, San Francisco. Detailed description of
the methods and results can be found in the published version of the paper (69). Briefly,
in order to determine what forms of RNA were produced from each variant identified in
Table 2.2, the 2.15 Kb fragment (of the region encompassing exons 20 – 20A including
the intronic region in between) from each sequence variant (from Table 2.2) was
digested with PciI and BsrFI to produce a 1731 bp fragment, which was used to create
minigene constructs in pcDNA3.1 vector using CMV promoter and a bGH polyA tail. The
design retains sequences from exons 20, 20A and 21, and parts of intronic region
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between 20 and 20A and 20A and 21. These constructs were individually transfected
into steroidogenic human adrenal NCI-H295A cells. After transfection, RNA splicing was
assessed by RT-PCR followed by electrophoresis in 2% agarose gels. To distinguish
the splicing products arising from the minigene constructs vs. those endogenously
expressed in NCI-H295A cells, we used the vector-specific primer for RT-PCR.
2.2.6. Statistical Analysis
The significance of the association of intron sequence variation with PCOS was
assessed using Pearson’s Chi Square Test. (P < 0.05, was considered significant).
2.3. Results
2.3.1. Genetic variants in the DENND1A gene
Data from WES performed on DNA obtained from unaffected control (n = 6) and PCOS
(n = 6) theca cell cultures were investigated to identify functional genetic variants in the
DENND1A gene. As shown in Table 2.1, only synonymous coding-sequence and
intronic variants were identified. No missense, splice-site or nonsense variants that
could contribute to alternative splicing of V2 were identified (42).
2.3.2. Copy Number Variations in the DENND1A gene
No copy number differences were found between unaffected control and PCOS theca
cell DNA by examining copy number changes in the WES data (6 control, 6 PCOS) as
well as by in vitro TaqMan Copy Number Assays (6 control, 8 PCOS). The qPCR results
from the in vitro Copy Number Assays targeting two regions (exon 2 – intron 2; exon 20
– intron 20) in the DENND1A gene are shown in Figure 2.2.
2.3.3. DENND1A.V2 arises by exonization of sequences in intron 20
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The NCBI database lists multiple DENND1A transcripts; V1 and V2 being the major
ones (42,66). Examining the coding regions of the V1 and V2 mRNAs showed that they
are identical through the end of exon 20 and then diverge. V1 continues with canonical
exons 21 and 22 to yield a 1009 AA open reading frame, while V2 lacks the sequences
encoded by exons 21 and 22 and has a different coding sequence that is responsible
for a 559 AA open reading frame with a unique C-terminal 33 AA. Using this sequence
in silico to probe the DENND1A gene, we found that the 33 AA C-terminus of V2 was
generated by exonization of sequences located ~1.5 kb downstream from canonical
exon 20 and 19.5 kb upstream from canonical exon 21 (Figure 2.3 A) Because this
“exonic” or coded sequence was flanked by intronic region on 5’end but not the 3’end,
(coding for a stop codon causing production of truncated isoform V2 with 559 AA), we
named this exon, cryptic exon 20A.
2.3.4. Intron 20 Sequence Variation
To determine if there is genetic variation in intron 20 that might give rise to alternative
splicing that might determine whether the DENND1A gene expresses mRNA encoding
DENND1A V1 vs. V2, genomic DNA from human leukocytes obtained from blood
collected from unaffected control (n = 20) women and women with PCOS (n = 19) as
well as from theca cell cultures obtained from unaffected control women (n = 8) and
women with PCOS (n = 9) was sequenced. Using primers S1626 and AS3776, we
amplified a 2.15 kb region and then used primers S1280 and AS1670 (Figure 2.3 B) to
sequence the PCR products. Sequencing identified a complex variable region 330 bp
upstream from exon 20A with an extended dinucleotide TG repeats. Direct sequencing
of this region in some genomic DNA samples yielded garbled sequence data,

29

suggesting the presence of multiple sequence variants. Therefore, we cloned the 2.15
kb product and then sequenced multiple clones and identified different sequence
variants (Figure 2.3 C). Among the 10 variants (variants 2 - 11) identified in genomic
DNA from unaffected and PCOS women, none appeared to be overrepresented in
PCOS women. Variants 2,4,9 and 11 were found in a limited number of samples from
theca cells, and variants 2 and 4 were only found in samples from PCOS patients. We
detected

known

SNPs

including

rs10739631,

rs45480399,

rs71490807,

and

rs10986007 (Figure 2.3 C) (69). The sequence variants were assessed and results are
represented in Table 2.2. None of the variants were significantly associated to PCOS (P
>0.05)
2.3.5. Minigene Analysis of alternative splicing.
Please note: minigene construction and splicing analysis were performed by Dr. Walter
Miller’s laboratory at the University of California, San Francisco. Detailed description of
the results can be found in the published version of the paper (69). Briefly, five splicing
products were obtained arising from the minigene constructs created with each of the
eleven variants shown in Figure 2.3 and Table 2.2. However, in two independent
experiments with all constructs, none of these consistently favored splicing to favor the
mRNA encoding the V2 isoform (69).
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Table 2.1. WES analysis of the DENND1A gene. DENND1A variants identified by
WES are described along with the calculated alternate allele frequencies in the control
(n = 6) and PCOS (n = 6) theca cell cultures. Alternate allele frequency in European
American population (obtained from Exome 6500) was reported for comparison. (42)
Location
SNP

Ref

Alt allele

Alt allele

Alt allele

Allele

Freq_Control

Freq_PCOS

Freq (EU)

Function
(Chr 9)

rs3739837

126143662

utr-3

G

A (0.083)

A (0.083)

A (0.1109)

rs2491348

126144746

Synonymous

T

C (1.0)

C (1.0)

T (0.0003)

rs2808409

126144758

Synonymous

T

C (1.0)

C(1.0)

ABSENT

rs2808411

126146197

Intron

C

G (1.0)

G (1.0)

C (0.082)

rs10739631

126164562

Intron

T

C (1.0)

C (1.0)

ABSENT

rs7872778

126201672

Intron

G

A (0.083)

Absent

ABSENT

rs62581072

126201742

Intron

G

Absent

A (0.083)

ABSENT

rs10739633

126202551

Intron

A

C (0.75)

C (0.75)

ABSENT

rs3829851

126219706

Synonymous

A

G (0.083)

Absent

G (0.055)

snp4115

126219742

Intron

C

Absent

T (0.083)

ABSENT

snp3842

126220063

Intron

G

Absent

T (0.083)

ABSENT

rs61736953

126220114

Synonymous

C

T (0.083)

T (0.166)

T(0.0884)

rs12377595

126439100

Intron

T

G (0.166)

G (0.33)

G (0.2490)

rs9785285

126520068

Synonymous

T

C (0.33)

C (0.166)

C (0.2123)

rs41274356

126531724

Intron

T

C (0.083)

Absent

C (0.0239)

rs1778890

126531755

Intron

T

C (0.33)

C (0.166)

C (0.2148)

snp3895

126554844

Intron

A

Absent

G (0.083)

ABSENT

rs670028

126641091

Intron

A

G (0.25)

Absent

ABSENT

Figure 2.2. Copy Number Analysis in the DENND1A gene. Results from TaqMan
Copy Number qPCR assays for regions overlapping exon 2 – intron 2 (2.2 A) and exon
20 – intron 20 (2.2 B) were analyzed in CopyCaller software and no copy number
differences between control (n = 6) and PCOS (n = 8) theca cells were observed.
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Figure 2.3. Diagram of the 3’ end of the DENND1A gene and intron 20 sequence
variants identified. A. Scale diagram of ~20 kb spanning DENND1A exons 20 and 21;
bases are numbered with the first base of exon 20 (Chr 9: 126145934), designated as
base 1; exons are shown as boxes. B. Magnified diagram of the region between exons
20 and 20A; the hypervariable region between the vertical dotted lines was identified by
sequencing PCR products generated with primers S1626 and AS3776. C. Sequence
variants in the hypervariable region with variant 1 depicting the WT sequence. Known
SNPs in this region are highlighted: green, rs10739631; cyan, rs45480399; purple,
rs71490807; grey, rs10986007. Newly identified variants at chr 9: 126164525 126164521 are highlighted in yellow. (69)
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Table 2.2. Intron 20 Sequence Variation. The intronic region between exons 20 and
20A was assessed in the genomic DNA from human leukocytes obtained from blood
collected from unaffected control (n = 20) women and women with PCOS (n = 19) as
well as from theca cell cultures obtained from unaffected control women (n = 8) and
women with PCOS (n = 9). The number of clones carrying each variant sequence
(shown in Figure 2.3 C) in normal and PCOS samples and the average number of
clones identified per sample for each variant are described.
Variant

No. of Clones with Variant Avg. No. of Clones with Variant per sample
Control

PCOS

Control

PCOS

1

65

42

3

2

2

0

2

NA

1

3

4

4

1

1

4

0

2

NA

1

5

18

20

3

2

6

9

23

3

2

7

18

28

2

2

8

6

2

1

1

9

2

2

2

2

10

3

0

2

NA

11

1

0

1

NA
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2.4. Discussion
Considering the established association between DENND1A and PCOS based on
genetic association studies (34–39), genotype-phenotype correlation studies (40,41), in
vitro functional studies (70) and its potential diagnostic and therapeutic applications
(67), it was first important to understand the mechanism of V2 production and
overexpression in PCOS theca cells. We report that the V2 isoform of the DENND1A
gene is produced by exonization of sequences in intron 20, which generates a unique
exon 20A, encoding the C-terminus of V2 (69).
This is a comprehensive study investigating several possible genetic mechanisms for
V2 overexpression in PCOS theca cells including sequencing analysis for coding region
and splice-site variants, copy number analysis, analysis of the intronic region between
exon 20 (present in both V1 and V2) and cryptic exon 20A (present in only V2). As
shown in the results none of these mechanisms appear to contribute to increased V2
expression in PCOS theca. The WES results are consistent with another study reporting
no changes in DENND1A exons or splice junctions in PCOS (71).
Genetic variation in the intronic region between exons 20 and 20A was identified.
However, when each of these sequence variants was tested in a mini gene system,
none of them consistently favored mRNA splicing to produce V2 instead of V1. Thus
increased V2 expression in PCOS theca cells does not appear to result from genomic
sequence variation in intron 20.
It is important to note that though none of the genetic mechanisms we investigated,
seemed to contribute to the observed V2 overexpression in PCOS theca cells, there
maybe other potential genetic mechanisms including promoter region variants, variants
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affecting mRNA stability (positively or negatively) in both DENND1A isoforms and
epigenetic mechanisms including DNA methylations, histone modifications and miRNA
regulation. Further investigation of these mechanisms contributing to V2 overexpression
in PCOS theca cells is warranted.
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Chapter 3: MiR-125a-3p targets DENND1A.V2 and contributes to the V2 mediated
steroidogenic phenotype in PCOS theca cells

Abstract
Polycystic ovary syndrome (PCOS) is a multisystem disorder with a complex
pathophysiology. Several microRNAs (miRNAs), small, non-coding post-transcriptional
gene regulators, are known to be differentially expressed in granulosa cells, follicular
fluid, ovarian stroma, and in the circulation of women with PCOS. However, there are no
reports on miRNA expression and target gene analysis in control and PCOS theca cells.
Understanding gene expression and its regulation in theca cells may represent a key to
understanding the hyperandrogenemia characteristic of PCOS. The previously reported
altered transcriptome profiles in PCOS theca cells could be explained, at least in part,
by miRNA regulation. In the present study, we identified 18 miRNAs, which are
differentially expressed in PCOS theca cells, some of which are predicted to target
PCOS candidate genes identified by Genome Wide Association Studies. Using
Ingenuity pathway analysis, we identified a common network with ~45% of the
differentially expressed miRNAs identified in this study, and 73% of the PCOS
candidate genes. In addition, miR-125a-3p, which was predicted to target DENND1A,
one of the PCOS candidate genes, was shown to have specific interaction for the
DENND1A.V2 isoform known to have a functional role in PCOS theca cell

36

steroidogenesis via correlation expression and mimic studies. In addition, miR-125a-3p
expression was also negatively correlated to DHEA accumulation and overexpression of
miR-125a-3p mimic also downregulated CYP17 mRNA expression. Our findings
suggest an epigenetic mechanism of V2 overexpression in PCOS theca cells via miR125a-3p and suggest that the PCOS candidate genes derived from GWAS are part of a
complex network regulated by miRNAs.

3.1. Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5% 7% women worldwide. The disorder is heterogeneous, characterized by a broad
spectrum

of

reproductive,

metabolic

and

endocrinological

features

including

hyperandrogenism, anovulation, infertility, and presence of multiple small subcortical
follicular cysts embedded in bilaterally enlarged ovaries (20,28,72,73). Other
endocrinopathies and metabolic features are commonly observed in PCOS patients
including abnormal glucose metabolism, insulin resistance, dyslipidemia and obesity.
PCOS women are known to have higher prevalence rates of type 2 diabetes (T2D),
metabolic syndrome and cardiovascular disease (10,72). Most consensus diagnostic
schemes recommend the presence of hyperandrogenism (clinical or biochemical) as an
essential characteristic for reaching a PCOS diagnosis, and it is considered to be the
hallmark

of

PCOS.

A

cross-sectional

case-control

study

suggested

that

hyperandrogenism is implicated in both the metabolic and reproductive morbidities of
PCOS, and maybe a common link between the two (9,20). Ovarian androgen
production is increased in PCOS and studies show that ovarian theca cells from PCOS
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women secrete more androgen than theca cells from regularly ovulating women
(21,22,74–76). Thus, understanding gene expression and its regulation in theca cells is
central to understanding PCOS pathophysiology, or at least hyperandrogenism
associated with PCOS. Wood et al. (77,78) have shown that PCOS theca cells have a
characteristic molecular signature as compared to normal theca cells. Although these
results revealed altered gene expression in PCOS theca as compared to normal theca
cells, it is not yet known whether the altered expression profile is the result of
transcriptional or post-transcriptional regulatory mechanisms.
MicroRNAs (miRNAs) are small (20-24 nucleotides) single-stranded, noncoding,
regulatory RNA molecules. They are involved in post-transcriptional regulation of gene
expression either by complimentary binding to the 3’ untranslated region of their target
mRNA, thereby inhibiting translation or inducing mRNA degradation (61,62). The posttranscriptional mechanism operationalized for down regulation of gene expression
depends upon the binding target sequence. Messenger RNA degradation occurs in
case of complete or near complete complementarity between miRNA and the target,
while repression or inhibition of translation occurs if there is not sufficient
complementarity for cleavage (62). Although not much is known about the roles of
miRNAs in PCOS pathophysiology, there have been studies providing evidence of
differential miRNA expression in the ovarian stroma, follicular fluid and granulosa cells
of women with PCOS (63,79–81). Metformin, an insulin-sensitizing drug, which is used
as a treatment to lower insulin and androgen levels and initiate ovulation in women with
PCOS, changes global miRNA expression patterns (82). MicroRNAs are also reported
to be stably expressed in encapsulated vesicles or free-circulating in the serum, plasma,
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urine and saliva, making them potential non-invasive biomarkers for PCOS diagnosis
(63).
Several genome-wide association studies (GWAS) have identified loci significantly
associated with PCOS. In a two-part study, GWAS on Han-Chinese populations
identified 11 candidate loci (34,35).

Subsequent GWAS on European populations

confirmed associations of some of the Han-Chinese GWAS to PCOS, and also
identified additional candidate loci (36,37). Together, the 4 GWA studies have identified
22 candidate loci for PCOS (Table 1.1, chapter 1), including DENND1A. Although some
of these loci consist of plausible PCOS candidate genes, the molecular mechanisms by
which most of the identified loci contribute to PCOS is not clearly understood. We
demonstrated that the total mRNA transcript as well as a splice variant of DENND1A,
DENND1A.V2, is increased in PCOS theca cells, with no change in the DENND1A.V1
(full-length isoform) transcript expression (70). Forced expression of DENND1A.V2 in
normal

theca

cells

increased

androgen

production,

whereas

knockdown

of

DENND1A.V2 expression in PCOS theca cells reduced androgen synthesis, implicating
DENND1A.V2 in the regulation of steroidogenesis and the PCOS phenotype (70). The
mechanisms underlying the increased DENND1A.V2 expression in PCOS theca cells,
as well as their altered transciptome signature in PCOS, remain to be elucidated. One
possibility is that these alterations result, in part, from differential expression of miRNAs.
However, a detailed study of miRNA expression and target gene analysis has not been
performed in theca cells.
In the present study, miRNA expression profiles of human theca cell cultures,
established from women with PCOS and without the disease were determined using
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next generation sequencing. Target gene analysis of the differentially expressed
miRNAs was focused on PCOS candidate genes identified by GWAS (34–37). Pathway
and Network analyses (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) were
performed on the differentially expressed miRNAs between normal and PCOS theca
cells identified in this study and the established GWAS candidate genes to identify a
common network that may be involved in PCOS pathophysiology. Expression patterns
of select miRNAs and target genes in the common network were validated by
quantitative real-time PCR and associations of differential expression patterns (of both
miRNAs and target genes) with androgen biosynthesis were investigated.

3.2. Materials and Methods
3.2.1 Cell culture: Human theca interna tissue was obtained from age-matched, normal
cycling women (n = 6) and women with PCOS (n = 5) undergoing hysterectomy,
following informed consent under a protocol approved by the Institutional Review Board
of The Pennsylvania State University College of Medicine as previously described (68).
Isolation of theca cells and theca cell cultures was done as described in Chapter 2. All
theca cell cultures used for the following experiments were treated with and without
20mM forskolin for 16 hours. Refer to Appendix, Table A.3.1 for details about samples
used for different assays performed.
H295R cells were obtained from ATCC and were cultured according to ATCC
recommended culture conditions.
3.2.2. MicroRNA Discovery Sequencing: MicroRNA discovery sequencing was
performed using the Illumina technology (by LC Sciences, www.lcsciences.com) on
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theca cell RNA from normal cycling women (n = 4) and women with PCOS (n = 4) each
treated with (F) and without (C) forskolin. Total RNA was extracted using TRIzol
reagents. Small RNA library prep, cDNA deep sequencing and initial data analysis
including alignment of raw reads to miRbase (v17) and normalization of count data was
performed by LC Sciences. The log2 normalized expression levels for each miRNA were
used for statistical analyses after filtering for human miRNAs.
3.2.3. Target identification and Pathway analysis: The miRNA target prediction filter
in Qiagen’s Ingenuity® Pathway Analysis tool (IPA®, QIAGEN Redwood City,
www.qiagen.com/ingenuity) was used to identify potential target genes for the 18
miRNAs that were differentially expressed between PCOS and normal theca cells (FDR
<

0.05).

MicroRNA-target

gene

relationships

having

a

confidence

level

of

“Experimentally Observed” or “High-Predicted” were considered. Pathway and network
analyses were also performed in IPA.
3.2.4. Quantitative RT-PCR based analysis of miRNA expression: Expression
patterns of select miRNAs were validated in vitro using the TaqMan MicroRNA Assays
(Life Technologies) following the manufacturer’s instructions. For the miRNA-qPCR
assays, total RNA was extracted from the established theca cell cultures (Normal: n = 5
and PCOS: n= 4; treated with and without forskolin) using miRVana miRNA isolation kit
(Ambion, Life Technologies) following manufacturer’s protocol. Briefly, 10 ng RNA was
reverse transcribed using the target (miRNA) specific stem-loop RT primer and the
TaqMan MicroRNA reverse transcription kit. The cDNA was then amplified by real-time
qRT-PCR using target specific TaqMan primer-probe mix. The qRT-PCR was
performed in triplicates per sample. Different small RNAs (RNU48, RNU43 and miR-16)
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were tested for consistent expression between PCOS and unaffected control theca cell
samples and RNU48 was selected for normalization of the qRT-PCR expression data.
The mean expression value for each miRNA was divided by the mean RNU48
expression value to normalize each sample.
3.2.5. Quantitative RT-PCR based analysis of DENND1A.V1, DENND1A.V2 and
CYP17 expression. Quantitation of DENND1A.V1, DENND1A.V2 and CYP17 mRNA
abundance was determined using the Single Step Brilliant III Ultra Fast SYBR qRT-PCR
Reagents (Agilent) using 50-100 ng total RNA/tube, and 200nM final concentration of
each forward and reverse primers, and 100nM probe. The gene specific one step PCR
was carried out in duplicate for each mRNA sample and for a series of dilutions in an
Mx3000p Thermocycler system (Stratagene) according to manufacturers instructions for
this instrument as previously described (70). The primer and probe sets utilized were
previously described (70). TATA Binding Protein (TBP) mRNA was used for
normalization based on our previous studies (70). The mean expression value for each
mRNA was divided by the mean TBP expression value to normalize each sample.
3.2.6. Quantitation of Dehydroepiandrosterone (DHEA): ELISA for DHEA was
performed on cell culture media without organic solvent extraction using kits from DRG
International, Inc. (Springfield, NJ) as described by the manufacturer’s protocol, and
normalized by cell count.
3.2.7. Mimic studies: H295R cells were transfected with miRVana hsa-miR-125a-3p
mimic and negative control-1 mimic (Life Technologies) at a concentration of 75 nM
using RNAiMAX transfection reagents and the manufacturer’s protocol. Cells were
harvested 48 hours post transfection and total RNA was extracted using miRVana
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miRNA isolation kit (Ambion Life Technologies) following the manufacturer’s protocol.
V1, V2 and CYP17 mRNA qPCRs were performed on control and miR-125a mimic
transfected RNA as described in section 3.2.5.
3.2.8. Statistical analysis: For miRNA discovery sequencing analysis, for each miRNA,
a one-way analysis of variance (ANOVA) model was fit to the log2 normalized
expression levels to identify miRNAs differentially expressed among the four groups Normal Untreated Control (Normal-C), Normal Forskolin Treated (Normal-F), PCOS
Untreated Control (PCOS-C) and PCOS Forskolin Treated (PCOS-F). After fitting the
ANOVA models for each miRNA, linear contrasts were used to test for differences
between the following group comparisons: Normal-C vs. Normal-F; PCOS-C vs. PCOSF; Normal-C vs. PCOS-C; Normal-F vs. PCOS-F and Untreated (Normal-C and PCOSC) vs. Treated (Normal-F and PCOS-F). Meta-analysis was performed on miRNAs
common between and having significant P < 0.05 in both group comparisons; Normal-C
vs. PCOS-C, and Normal-F vs. PCOS-F. Their individual P values were combined
using Fisher’s method (83) for combining P values to get an overall comparison of
miRNA expression between PCOS and normal theca cells. Subsequently, the combined
P values were used to obtain the false discovery rate (FDR) using the Benjamini and
Hochberg method (84). MicroRNAs having a statistically significant expression
difference between both pair-wise comparisons (Normal-C vs. PCOS-C and PCOS-F
vs. PCOS-F), a meta-analysis combined P < 0.05 and FDR < 0.05 were considered
significant. All statistical analyses were performed using R (85).
For the miRNA qRT-PCR assays, two sample t-tests were performed to test for
differences between groups Normal-C vs. PCOS-C and Normal-F vs. PCOS-F. The P
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values thus obtained were combined using Fisher’s method (83) and combined P < 0.05
were considered statistically significant. Each miRNA specific cDNA was run in
triplicates for the qRT-PCR assays.
The results from mRNA qRT-PCR (DENND1A.V1 and DENND1A.V2) and steroid
(DHEA) were collected from individual patients and ANOVA was performed to test for
differences. P values were determined by the Bonferroni method for multiple
comparisons. Data are presented and described in the text as the mean ± SEM
performed triplicate and were prepared using Prism 5.0c (GraphPad Software, San
Diego, CA).
Spearman’s nonparametric correlation coefficient (ρ) was calculated to estimate the
degree of correlation between all pairwise comparisons. (ρ was considered significant
when P < 0.05). Please note that all samples treated with (F) and without (C) forskolin
were considered together for the statistical analysis, giving a total of 10 unaffected
control and 8 PCOS samples for Spearman’s correlation testing. Performing statistical
tests for treated and untreated samples individually gave insignificant results owing to
small sample size (n = 5 control unaffected; n = 4 PCOS samples)

3.3. Results
3.3.1. PCOS theca cells have differential miRNA expression as compared to
Normal theca cells: A total of 1,823 miRNAs were identified from deep sequencing.
After meta-analysis of the Normal-C vs. PCOS-C and Normal-F vs. PCOS-F pairwise
comparisons, 18 miRNAs were found to be significantly differentially expressed
between normal and PCOS theca cells (Fisher’s combined P < 0.05) with a FDR < 0.05
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(Table 3.1). Of these 18 miRNAs, 13 miRNAs had increased expression and 5 miRNAs
had decreased expression in PCOS theca cells as compared to unaffected control
theca cells.
3.3.2. Differentially expressed miRNAs in PCOS theca are predicted to target
known PCOS candidate genes: The 18 miRNAs listed in Table 3.1 were used for
bioinformatics analysis including target prediction and pathway analysis in IPA as
described below. The miRNA target prediction filter in IPA was used to identify the
validated and predicted target genes of the differentially expressed miRNAs (the
miRNA-target gene relationships with IPA described confidence level of “Experimentally
Observed” and “High-Predicted”) and a total of 6443 such interactions were identified.
Interestingly 6 of the 18 miRNAs described in Table 3.1, were predicted to target
(confidence level = High Predicted) 12 of 22 PCOS GWAS candidate genes identified in
Han-Chinese (34,35) and European populations (36,37) and described in Table 1.1
(Chapter 1). The predicted miRNA-GWAS gene interactions are shown in Table 3.2.
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Table 3.1. Differentially expressed miRNAs in unaffected control and PCOS theca
cells.

Using MicroRNA Discovery Sequencing, 18 miRNAs were differentially

expressed between unaffected control vs. PCOS theca cells, 13 of which were
upregulated and 5 were down-regulated in PCOS theca cells compared to normal.
(Fisher’s combined P value < 0.05 and FDR < 0.05 considered significant)

ID
(hsa)

PCOS/
Control
(C)

P value
PCOS vs.
Control
(C)

PCOS/
Control
(F)

P value
PCOS vs.
Control
(F)

meta
P value

meta
FDR

miR-501-3p

6.31

2.13E-06

5.56

5.20E-06

2.90E-10

5.29E-07

miR-100-5p

4.89

4.74E-06

3.90

2.83E-05

3.19E-09

2.43E-06

miR-409-5p

9.27

4.66E-06

6.51

3.65E-05

4.00E-09

2.43E-06

miR-125a-3p

0.69

9.19E-06

0.76

1.17E-04

2.32E-08

1.06E-05

miR-1271-5p

7.44

8.83E-05

5.61

3.70E-04

5.95E-07

2.17E-04

miR-1301-3p

2.70

1.04E-03

3.08

2.87E-04

4.79E-06

1.45E-03

miR-130b-3p

0.61

3.63E-04

0.72

6.70E-03

3.39E-05

8.23E-03

miR-99b-5p

2.79

7.42E-04

2.37

3.51E-03

3.61E-05

8.23E-03

miR-127-3p

2.15

1.72E-04

1.42

2.86E-02

6.45E-05

1.31E-02

miR-148b-5p

0.69

1.55E-03

0.75

6.33E-03

1.23E-04

2.18E-02

miR-654-5p

2.41

1.72E-04

1.37

6.35E-02

1.35E-04

2.18E-02

miR-195-5p

0.46

8.74E-04

0.62

1.33E-02

1.44E-04

2.18E-02

miR-744

1.48

2.10E-03

1.36

1.00E-02

2.48E-04

3.29E-02

mir-1293

2.05

8.56E-03

2.31

2.80E-03

2.78E-04

3.29E-02

miR-410-3p

1.69

1.30E-03

1.41

1.92E-02

2.90E-04

3.29E-02

0.31

9.42E-04

0.50

2.67E-02

2.91E-04

3.29E-02

1.77

1.52E-02

2.22

1.75E-03

3.07E-04

3.29E-02

2.53

5.50E-03

2.60

5.95E-03

3.71E-04

3.76E-02

miR-4524a5p
hsa-miR502-3p
hsa-miR494-3p
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Table 3.2. MiRNAs targeting GWAS genes. MiRNA target identification (IPA) filter
identified 6 of the differentially expressed miRNAs with predicted interactions with 12 of
the 22 GWAS genes previously identified (listed in Table 1).
ID

Targeted Gene

Source

IPA Confidence

hsa-miR-125a-3p
hsa-miR-1271-5p

DENND1A
TOX3

TargetScan Human
TargetScan Human

High (predicted)
High (predicted)

hsa-miR-1271-5p

ERBB4

TargetScan Human

High (predicted)

hsa-miR-130b-3p

DENND1A

TargetScan Human

High (predicted)

hsa-miR-130b-3p

ZNF217

TargetScan Human

High (predicted)

hsa-miR-130b-3p

RAB5B

TargetScan Human

High (predicted)

hsa-miR-130b-3p

ERBB4

TargetScan Human

High (predicted)

hsa-miR-130b-3p

ERBB3

TargetScan Human

High (predicted)

hsa-miR-130b-3p

KCNA4

TargetScan Human

High (predicted)

hsa-miR-195-5p

INSR

TargetScan Human

High (predicted)

hsa-miR-195-5p

YAP1

TargetScan Human

High (predicted)

hsa-miR-195-5p

HMGA2

TargetScan Human

High (predicted)

hsa-miR-195-5p

RAD50

TargetScan Human

High (predicted)

hsa-miR-410-3p

HMGA2

TargetScan Human

High (predicted)

hsa-miR-654-5p

GATA4

TargetScan Human

High (predicted)
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3.3.3. A common network of differentially expressed miRNAs and PCOS
candidate genes may be at work in the PCOS theca: Target prediction revealed that
~33 % (6/18) of the miRNAs that are differentially expressed between unaffected control
and PCOS theca cells are predicted to target 55% (12/22) of the GWAS candidate
genes including DENND1A, which has been previously shown to have a functional role
in PCOS theca cell steroidogenesis. This led us to hypothesize that like DENND1A,
other PCOS GWAS candidates may also have significant functional and biological
relevance to the disorder, possibly in a common network. To test this in silico, IPA core
pathway analysis was performed on all of the 22 GWAS genes identified thus far to
examine pathways, networks, diseases and bio-functions that are “over-represented” in
the GWAS candidates. Several PCOS relevant features were identified in the canonical
pathways, diseases and biofunctions, physiological system development and functions
that were over-represented in the GWAS genes dataset and are listed in Table 3.3.
These results suggested that at least some of the 22 GWAS candidate genes and the
differentially expressed miRNAs might be involved in a common pathway/ network with
functional relevance to PCOS pathophysiology central to the theca cells. To investigate
this, we utilized the “Build Network” application available in IPA and created a network
with the 22 GWAS genes and overlayed the 18 differentially expressed miRNAs and
using the “grow” option added any known or predicted connections present in the
Ingenuity Knowledge Base. The resulting network is represented in Figure 3.1. As
shown, ~73% (16/22) of PCOS GWAS candidate genes and ~44% (8/18) of
differentially expressed miRNAs in PCOS theca are a part of a common network.
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Table 3.3. Ingenuity Pathway Analysis of the PCOS risk loci reported to date. Key
findings from the pathway analysis (performed in IPA) of the 22 loci (Table 1.1)
associated with PCOS risk are described. The Top Canonical Pathways (3.3.A), Top
Diseases and Bio-functions (3.3.B) and Physiological System Development and
Functions (3.3.C) over-represented in the PCOS risk loci are shown.
3.3.A. Top Canonical Pathways
Name
Agrin interactions at Neuromuscular Junction
ErbB Signaling
Neuregulin Signaling
Ovarian Cancer Signaling
ErbB2-ErbB3 Signaling

P value
3.80E-05
7.35E-05
7.87E-05
2.56E-04
1.35E-03

Overlap
4.30%
3.50%
3.40%
2.30%
3.50%

3.3.B. Top Diseases and Bio-functions
Name
Cancer
Organismal Injury and Abnormalities
Respiratory Disease
Endocrine System Disorders
Reproductive System Disease

P value
9.61E-04 - 4.31E-11
9.61E-04 -4.31E-11
4.34E-04 - 4.38E-10
9.60E-04 - 6.83E-09
9.60E-04 - 6.83E-09

# Molecules
20
20
6
12
17

3.3.C. Physiological System Development and Function
Name
Organ Development
Reproductive System Development and Function
Organ Morphology
Renal and Urological System Development and
Function
Organismal Development
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p-value
9.60E-04 - 4.46E-09
9.60E-04 - 4.46E-09
9.6E-04 - 2.81E-08

# Molecules
9
10
10

8.80E-04 - 2.81E-08

7

9.60E-04 - 1.44E-07

10

Figure 3.1. IPA network of miRNAs and PCOS candidate genes. Common network
of the 16/22 PCOS candidate genes and 8/18 of the differentially expressed miRNAs is
shown. IPA pathway figure legend is described as well.
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3.3.4. qRT-PCR validation of miRNA expression: Next, we determined the
expression patterns of all the 8 miRNAs in Figure 3.1. in vitro in 5 unaffected control and
4 PCOS theca cell cultures treated with and without 20 mM forskolin by TaqMan-based
miRNA qPCR assays (Life Technologies). Of the 8 miRNAs, statistically significant
expression differences (P < 0.05) between unaffected control and PCOS theca cells
were only observed for hsa-miR-125a-3p (Figure 3.2.A) and hsa-miR-130b-3p (Figure
3.2.B). miR-125a-3p expression was significantly downregulated in PCOS theca cells
under both basal and forskolin stimulated conditions. MiR-130b-3p expression was
reduced in PCOS theca cells only under basal conditions. There were no significant
changes in miR125a-3p and miR-130b-3p expression in response to forskolin treatment
in unaffected control and PCOS theca cells.
3.3.5. Decreased miR-125a-3p expression is correlated to increased DENND1A.V2
expression in PCOS theca cells. Since both miR-125a-3p and miR-130b-3p are
predicted to target DENND1A, we sought to determine the relation between their
expression patterns in theca cells. As shown in Figure 3.3, expression of both miRNAs
was compared against expression of both isoforms of DENND1A, DENND1A.V1 and
DENND1A.V2, in the same unaffected control (n = 5) and PCOS (n = 4) samples
treated with and without forskolin. A significant negative correlation was observed
between expression of miR-125a-3p and DENND1A.V2 (Figure 3.3.A) but no significant
relation with DENND1A.V1 expression was observed (Figure 3.3.B). No significant
correlations (P > 0.05) were observed between miR-130b-3p and DENND1A.V2 or
DENND1A.V1
In silico miRNA-mRNA target prediction strength was assessed for miR-125a-3p and
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both isoforms of DENND1A in microRNA.org, which utilizes predicted miR-target
interactions from miRanda and predicts the probability of miRNA downregulating gene
expression by calculating mirSVR scores. Positive or miRSVR scores = 0 indicate a null
probablility of interaction and higher negative scores indicate increasing probability of
interaction. miR-125a-3p alignment with 3’UTR of DENND1A.V1 gave a mirSVR score =
-0.0004, whereas miR-125a-3p alignment with 3’UTR of DENND1A.V2 (not present in
V1) gave a mirSVR score = -1.0634. This preliminary in silico analysis supported our
observed expression correlation results described above suggesting that the predicted
interaction of miR-125a-3p with DENND1A is likely more specific for DENND1A.V2 than
for DENND1A.V1 in theca cells.
3.3.6. Decreased miR-125a-3p expression in PCOS theca cells is correlated with
increased DHEA production. Because a relationship between reduced miR-125a-3p
expression and increased DENND1A.V2 expression was established and as increased
DENND1A.V2 expression in PCOS is known to be associated with increased androgen
production (70), we sought to determine whether miR125a-3p expression was
associated with increased androgen biosynthesis. We examined DHEA accumulation in
the matched 5 unaffected control and 4 PCOS theca cell preparations under the same
conditions. As shown in Figure 3.4.A, miR-125a-3p expression has a significant
negative correlation with DHEA accumulation in theca cells. Interestingly, miR-130b-3p
(Figure 3.4.B) expression also showed a negative correlation with DHEA accumulation
but not as significant as with miR-125a-3p and DHEA.
3.3.7. MiR-125a-3p overexpression in H295R cells downregulates V2 and CYP17
mRNA expression, but has no effect on V1 expression.
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In order to confirm specific interaction of miR-125a-3p with V2 and its impact on
androgen production (as shown by DHEA accumulation), we overexpressed miR-125a3p mimic in H295R cells (adrenal corticocarcinoma cell line) and analyzed V1, V2 and
CYP17 mRNA expression by qRT-PCR in negative-control and mimic treated cells. As
shown in Figure 3.5.A, mimic treated H295R cells showed a significant decrease in V2
expression (P = 0.042) when compared to control treated cells. No change in V1
expression was observed (Figure 3.5.B). In addition, CYP17 expression was also
significantly downregulated upon mimic overexpression as compared to control, which
was in agreement to the miRNA-DHEA correlation data shown in Figure 3.4.
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Figure. 3.2. Decreased miR-125a-3p and miR-130b-3p expression in PCOS theca
cells. miR-125a-3p and miR-130b-3p expression was compared, by qRT-PCR, in theca
cells propagated from 5 individual unaffected control and 4 individual PCOS women that
were treated in the absence (C) and presence of 20 mM forskolin (F) for 16 h. As
shown, both, miR-125a-3p (A) and miR-130b-3p (B) expression was decreased in
PCOS theca cells under basal conditions as compared to unaffected control cells.
However, only miR-125a expression was significantly reduced under forskolin
stimulated conditions (*P<0.05)
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Figure. 3.3. Decreased miR-125a-3p expression is correlated with increased
DENND1A.V2 expression. qRT-PCR miRNA expression of miR-125a-3p and miR130b-3p was compared with qRT-PCR mRNA expression of DENND1A.V1 and
DENND1A.V2 in same normal (n = 5) and PCOS (n = 4) theca cells. MiR-125a-3p
expression showed significant negative correlation (Spearman’s ρ = -0.52, P = 0.0279)
with DENND1A.V2 expression (3.3.A) but showed no significant relation with expression
of DENND1A.V1 (3.3.B) (Spearman’s ρ = 0.41, P = 0.0874). MiR-130b-3p expression
showed no significant relationships (P > 0.05) with both DENND1A.V2 (3.3.C) as well as
DENND1A.V1 (3.3.D), but showed a trend of negative correlation with DENND1A.V2
(3.3.C, Spearman’s ρ = -0.36) but not with DENND1A.V1 (3.3.D, Spearman’s ρ = 0.39).
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Figure. 3.4. Decreased miRNA expression is correlated with increased DHEA
accumulation. qRT-PCR miRNA expression of miR-125a-3p and miR-130b-3p was
compared with DHEA accumulation (estimated by ELISA) from same unaffected control
(n = 5) and PCOS (n = 4) theca cell cultures. Significant negative correlation with DHEA
accumulation was observed with miRNA expression of both miR-125a-3p (3.4.A,
Spearman’s ρ = -0.56, P = 0.0156) and miR-130b-3p (3.4.B, Spearman’s ρ = -0.48, P =
0.0408)
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Figure. 3.5. MiR-125a-3p overexpression in H295R cells downregulates V2 and
CYP17 mRNA expression, but has no effect on V1 expression. qRT-PCR mRNA
expression for V1, V2 and CYP17 genes was analyzed in H295R cells treated with miR125a-3p mimic (75nM) and negative control mimic (75nM) for 48 hours. MiR-125a-3p
overexpression causes a down-regulation of V2 (P = 0.042) and CYP17 (P = 0.0237)
mRNA expression when compared to control. No significant differences in V1
expression were observed (P > 0.05).
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3.4. Discussion
PCOS is a complex disorder. Recent GWAS have identified candidate loci, some of
which have been replicated by multiple laboratories, providing a basis for the molecular
dissection of the pathophysiology of PCOS (34–37). Theca cells, the androgen
producing cells of the ovary and central to PCOS pathophysiology, also have evidence
of an altered transcriptome profile in PCOS, which could be contributed by, at least in
part, by miRNA regulation. (77,78). However, a detailed study of miRNA expression and
target gene analysis has not been performed in theca cells. Altered miRNA levels have
been associated with several phenotypes in the PCOS spectrum including diabetes,
insulin resistance and inflammation. An increasing number of studies are showing
differential miRNA expression in the ovarian stroma, follicular fluid, cumulus cells and
granulosa cells of women with PCOS (63,64,79–81,86,87). Our study is the first to
identify differential miRNA expression in theca cell cultures from PCOS women as
compared to normal cycling women.
The first GWAS conducted on Han Chinese populations identified 11 loci with significant
associations with PCOS (34,35). The association of some of the loci identified in these
studies including DENND1A, RAB5B and THADA to PCOS has also been replicated in
European populations (38–40). Subsequent GWAS conducted on women of European
descent identified other loci including ERBB2, ERBB3, ERBB4, RAD50, KRR1, FSHB,
GATA4, NEIL2 and KCNA4 and also replicated association of some of the Han Chinese
GWAS including YAP1, THADA, DENND1A and C9orf3 (36,37). Of the total 22 loci
identified in the 4 GWAS, association with some candidate genes including INSR,
FSHR, LHCGR and GATA4 is plausible because of their known roles in reproductive
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biology /ovarian function and their involvement in PCOS candidate gene studies. For
e.g. FSHR and LHCGR are gonadotropins involved in regulation of folliculogenesis and
ovulation. The INSR gene is involved in insulin metabolism and can play a crucial role in
PCOS pathophysiology via insulin resistance. GATA4 is a transcription factor known to
be differentially expressed in PCOS granulosa and theca cells and is speculated to be
involved in transcriptional activation of PCOS relevant genes including CYP17, which is
responsible for androgen production. (8,24). However, the functional relevance of the
remaining loci with PCOS is not clear and the exact molecular mechanism by which any
of these candidate genes may contribute to the disorder is not known. Genotypephenotype correlation studies of the susceptibility SNPs identified by GWAS have
yielded low to modest relative risk ratios (41,88). This is not unexpected for a complex
disorder like PCOS and establishing a causal relationship between the genetic variants
identified in GWAS and pathophysiological phenotype is challenging. In a previous
study, we demonstrated that a splice variant (DENND1A.V2) of DENND1A, one of the
candidate genes identified in the Han Chinese GWAS and replicated in studies of
women of European ancestry is involved in PCOS theca cell steroidogenesis (69,70). In
the present study, we show that 6 of the 18 differentially expressed miRNAs in PCOS
theca cells are predicted to target 12 of the 22 PCOS candidate genes identified in
GWAS including DENND1A.
IPA pathway analysis of the 22 GWAS genes revealed an over-representation of
several PCOS relevant features. Three of the top 5 canonical pathways are central to
ovarian function and PCOS pathophysiology including ovarian cancer signaling, ErbB
signaling and ErbB2-ErbB3 signaling. Although there is no firm evidence for
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associations between PCOS and ovarian cancers because of limited sample sizes and
confounding risk factors, perturbation of pathways in ovarian cancer are important for
normal ovarian function (89). Ovarian morphology is altered in PCOS, which can be
explained by changes in cellular growth and proliferation pathways, which overlap with
ovarian cancer signaling. ErbB2, ErbB3 and ErbB4 are epidermal growth factors
receptors, and EGFR signaling plays a crucial role in ovarian steroidogenesis and
oocyte maturation (90,91). GWAS genes also show an over-representation of diseases
and disorders that are highly concordant with PCOS including organismal injury and
abnormalities, endocrine system disorders and reproductive system disorders, with 20,
12 and 17 molecules respectively, from the GWAS genes dataset being significantly
overrepresented in these diseases/ disorders. The physiological system development
and functions also had similar trends with organ development, reproductive system
development and function as well as organ morphology with 9, 10 and 10 molecules
respectively. The top IPA network which had ~45% (10/22) of the GWAS genes had a
network score of 24 and associated network functions including cancer, organismal
injury and abnormalities and respiratory disease. These results suggested that more
than one PCOS candidate gene are involved in PCOS pathophysiology, which warrants
detailed study of other GWAS candidate genes in a PCOS context for e.g. compare
gene expression patterns of the GWAS candidate genes in control unaffected and
PCOS theca cell cultures.
Overlaying the GWAS genes network with the 18 differentially expressed miRNAs
identified in this study revealed ~73% (16/22) PCOS GWAS candidate genes and ~44%
(8/18) differentially expressed miRNAs in PCOS theca to be a part of a common
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network. Our qPCR assays validated the expression patterns of some of these miRNAtarget gene pairs in vitro in theca cells, including hsa-miR-125a-3p and hsa-miR-130b3p down-regulation and increased expression of DENND1A isoform DENND1A.V2 in
PCOS theca cells.
There are studies demonstrating that hsa-miR-93 is differentially expressed in PCOS,
with evidence for decreased expression in human PCOS blastocysts (92) and increased
expression in human PCOS adipocytes (93), granulosa cells (94) as well as in
circulation (95). Target identification in IPA revealed that miR-93 is predicted to target
(“High” confidence level) 3 of the 11 GWAS genes: RAB5B, ZNF217 and THADA.
However, we did not find any differences in miR-93 expression levels in PCOS theca
cells in our sequencing as well as TaqMan based qPCR assays
It is important to note that this study provides further evidence for the functional role
played by DENND1A in PCOS as both the miRNAs, hsa-miR-125a-3p and hsa-miR130b-3p, whose differential expression in PCOS theca has been validated in vitro, are
predicted to target the DENND1A. The gene is also a part of the common network
shown in Figure 3.1. In addition, decreased miR-125a-3p expression is correlated with
increased DENND1A.V2 expression and increased DHEA accumulation, which is
characteristic of PCOS cells. The miR-125a-3p mimic studies in addition confirmed that
the predicted interaction of miR-125a-3p & DENND1A is specific for V2 and not V1.
Decreased miR-125a-3p expression can possibly explain, at least in part, the V2
overexpression in PCOS theca cells as documented previously, which was not
explained by any of the other genetic mechanisms investigated by Tee et al and
described in Chapter 2 in this thesis. (42,69). MiRNAs are usually involved in complex
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regulatory networks and their expression patterns are themselves regulated by several
factors. Even though a significant association between miR-130b-3p and DENND1A.V2
was not observed, a trend for inverse correlation with DENND1A.V2 but not V1 was
found and miR130-3p was inversely correlated with DHEA production. Thus, further
investigation of miR130-3p with respect to PCOS pathophysiology is warranted.
In addition to DENND1A and miR-125a-3p and miR-130b-3p, there are other genes in
the network that deserve further discussion including YAP1 and ZNF217. Though not a
lot is not known about these genes in the context of reproduction, we have evidence
showing that an isoform of YAP1 – YAP1.V2 and ZNF217 are significantly
downregulated in PCOS theca cells as compared to unaffected control theca cells and
reduced expression is correlated with increased DHEA accumulation. (Data not shown)
MiRNA - target gene interactions are complex and as mentioned above, correlated
inverse expression patterns are not always possible to observe as each gene can be
regulated by multiple miRNAs. Performing luciferase-reporter assays is crucial to
confirm the miRNA-target gene interaction in vitro. Even though, expression patterns
are not directionally correlated with the expression patterns of the miRNAs predicted to
target these genes, it is important to note that two other PCOS GWAS candidate genes
from the same network show evidence for differential expression associated with
functional relevance of increased androgen production that is central to PCOS.
These results suggest a potential epigenetic mechanism (in lieu of miRNA regulation) of
V2 overexpression in PCOS theca cells via miR-125a-3p regulation. These results also
support our hypothesis that miRNAs and DENND1A are involved in a complex network,
perhaps in combination with other GWAS genes and can explain the ovarian
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hyperandrogenemia associated with and central to PCOS.
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Chapter 4: Rare Mutations and Potentially Damaging Missense Variants in Genes
Encoding Fibrillar Collagens and Proteins Involved in Their Production Are
Candidates for Risk for Preterm Premature Rupture of Membranes

Please note: This chapter is under review at PLoS One as
Bhavi Modi, Maria Teves, Laurel Pearson, Hardik Parikh, Piya Chaemsaithong, Nihar
Sheth, Tim York, Roberto Romero, Jerome Strauss. Rare Mutations and Potentially
Damaging Missense Variants in Genes Encoding Fibrillar Collagens and Proteins
Involved in their Production are Candidates for Risk for PPROM.

Abstract
Preterm premature rupture of membranes (PPROM) is the leading identifiable cause of
preterm birth with ~ 40% of preterm births being associated with PPROM and occurs in
1% - 2% of all pregnancies. We hypothesized that multiple rare variants in fetal genes
involved in extracellular matrix synthesis would associate with PPROM, based on the
assumption that impaired elaboration of matrix proteins would reduce fetal membrane
tensile strength, predisposing to unscheduled rupture. We performed whole exome
sequencing (WES) on neonatal DNA derived from pregnancies complicated by PPROM
(49 cases) and healthy term deliveries (20 controls) to identify candidate
mutations/variants. Genotyping for selected variants from the WES study was carried

64

out on an additional 188 PPROM cases and 175 controls. All mothers were selfreported African Americans, and a panel of ancestry informative markers was used to
control for genetic ancestry in all genetic association tests. In support of the primary
hypothesis, a statistically significant genetic burden (all samples combined, SKAT-O pvalue = 0.0225) of damaging/potentially damaging rare variants was identified in the
genes of interest - fibrillar collagen genes, which contribute to fetal membrane strength
and integrity. These findings suggest that the fetal contribution to PPROM is polygenic,
and driven by an increased burden of rare variants that may also contribute to the
disparities in rates of preterm birth among African Americans.

4.1. Introduction
Although there is strong evidence from twin-based studies that both maternal and fetal
genetic factors contribute to preterm birth, attempts to identify specific loci contributing
to prematurity in genome-wide association studies (GWAS) have largely failed to yield
robust and reproducible findings (54,59,96–98). A number of candidate gene
association studies have found significant relationships, but meta-analyses indicate that
these associations are at best weak or population-specific (50,99,100). The
disappointing output from genetic studies may relate to the subject inclusion and
exclusion criteria, including the proximate cause of preterm birth - spontaneous preterm
birth (sPTB) or preterm premature rupture of membranes (PPROM), population
heterogeneity (partially attributable to genetic admixture), and environmental exposures,
including viral and bacterial infections. Further, identification of genetic variants
contributing to preterm birth risk is mostly based on the “common disease-common
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variant” hypothesis, which assumes that a large number of common allelic variants can
explain the genetic variance in complex diseases. This approach has been employed
for several complex traits such as human height and schizophrenia and despite having
large sample sizes required for success, there still exists an issue of “missing
heritability” with identified variants being able to explain only a small fraction of the
genetic variance observed (101). Considering the complex genetic nature of preterm
birth, a systematic identification of even a small number of rare variants with moderatelarge effect sizes in genes of known/putative biological significance can be helpful
(54,102). None of the genetic studies on preterm birth so far have taken this approach.
PPROM is the leading identifiable cause of preterm birth, with ~40% of preterm
deliveries being associated with PPROM (48). Previous studies have focused on
selected candidate genes involved in infection/ inflammation pathways, with the majority
of these studies investigating only maternal genomes (47,50,60,103,104) despite
evidence of a fetal contribution established by twin studies (59,97).
Human fetal membranes consist of an inner layer, the amnion, and an adherent outer
layer, the chorion. The amnion is the load-bearing component of the fetal membranes
and major contributor to their structural integrity. The strength of the fetal membranes is
influenced by both synthesis and degradation of the extracellular matrix (ECM)
components. Fibrillar collagens and associated proteins are major components of the
fetal membranes contributing to their tensile strength (105,106). Thus, defects in the
fibrillar collagen synthesis and/or altered ECM metabolism can adversely affect fetal
membrane integrity, and may result in preterm birth as a result of preterm rupture.
Epidemiological studies show that fetuses/neonates with Ehlers-Danlos syndrome,
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osteogenesis imperfecta, and restrictive dermopathy, disorders of ECM synthesis, are
at increased risk of adverse pregnancy outcomes including PPROM (106–109).

In

addition, a functional promoter SNP in the SERPINH1 gene, which encodes a
chaperone protein (HSP47) necessary for fibrillar collagen synthesis, was previously
shown to be associated with PPROM (110).
The primary hypothesis explored in this study is that PPROM is the result of rare
mutations or variants in the fetal genes involved in the elaboration of the amnion ECM.
An initial Whole Exome Sequencing (WES) was performed followed up by genotyping of
select variants in additional samples of neonatal DNA from normal term pregnancies
(controls) and pregnancies complicated by PPROM (cases). All of the neonates were
delivered from mothers of self-reported African-American ancestry.

In an effort to

identify functional variants with large effect, the analysis was selectively focused on
damaging mutations: either nonsense mutations or frameshift mutations that precluded
production of a functional protein, and missense mutations, which were predicted to be
damaging or potentially damaging. Furthermore, the investigation was restricted to
genes whose disruption could theoretically promote PPROM by weakening the fetal
membranes by disruption of the ECM fibrillar collagens and genes encoding proteins
involved in their production.
We discovered that rare heterozygous, nonsense, frameshift and damaging missense
mutations were more prevalent in the genomes of neonates born of pregnancies
complicated by PPROM as compared to normal term controls. The combined burden of
the rare damaging variants identified in the fetal genome yielded a statistically
significant genetic association with PPROM. These results suggest that PPROM may
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be caused by infrequent genetic variants that modulate fetal membrane strength leading
to weakening of the membranes and ultimately ending in premature rupture.

4.2. Materials and Methods
4.2.1. Study Population: The initial WES was performed on 49 case and 20 healthy
term control neonatal DNA samples. Additional genotyping of select variants was
performed on an independent cohort of 188 case and 175 control neonatal DNA
samples. Subjects were self-reported African-American women and their neonates
receiving obstetrical care at MCV Hospitals, Richmond, VA (all samples in the initial
WES) and Hutzel Hospital in Detroit, MI. The study was approved by the respective
Institutional Review Boards and written informed consent was obtained from mothers
before sample collection. Demographic and clinical data were obtained from surveys
and medical records. Control DNA samples (n = 20 + 175) were obtained from neonates
of singleton pregnancies delivered at term (> 37 weeks of gestation) of mothers with no
prior history of PPROM or preterm labor. Cases of PPROM (n = 49 + 188) were defined
as neonates from pregnancies complicated by spontaneous rupture of membranes prior
to 37 weeks of gestation. The diagnosis of membrane rupture was based on pooling of
amniotic fluid in the vagina, amniotic fluid ferning patterns and a positive nitrazine test.
Women with multiple gestations, fetal anomalies, trauma, connective tissue diseases
and medical complications of pregnancy requiring induction of labor were excluded.
4.2.2. Ancestry Estimates: Genetic ancestry was estimated to control for the presence
of population structure in all genetic association tests. Genetic ancestry estimates were
generated in a two-way model of admixture, European and West African, for the
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neonates of each self-reported African-American study subject using 102 ancestry
informative markers (AIMs), single nucleotide polymorphisms with large allele frequency
differences between ancestral populations (Appendix, Table A.4.1). Prior allele
frequencies derived from the HapMap West Africans (YRI, Yoruba in Ibadan, Nigeria)
and Europeans (CEU, CEPH Utah residents with ancestry from northern and western
Europe) were used to estimate individual genetic ancestry estimates following a
maximum likelihood approach with mean allele frequency difference between ancestral
populations (δ = 0.733) (111–113).
4.2.3. Whole Exome Sequencing: Whole Exome Capture and Sequencing was
performed on the initial set of samples at BGI (BGI, Cambridge, MA) using the
SureSelect Target Enrichment System Capture Process and high-throughput
sequencing on an Illumina HiSeq2000 platform. Raw image files are processed by
Illumina base calling Software 1.7 for base calling with default parameters and the
sequences of each individual are generated as 90bp paired-end reads. The raw
sequence data generated from the Illumina pipeline were used for bioinformatic
analysis.
4.2.4. Read Mapping and pre-processing: Raw sequence data for each individual
were mapped to the human reference genome (build hg19) using the BWA-MEM
algorithm of Burrows-Wheeler Aligner (v 0.7.12) (114). This was followed by a series of
pre-processing steps – marking duplicates, realignment around indels and base quality
recalibration. PCR duplicates were marked within the aligned reads using Picard tools.
(http://picard.sourceforge.net) Next, mapping artifacts around indels were cleaned up
using the RealignerTargetCreator, the IndelRealigner and the LeftAlignIndels walkers of
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the Genome Analysis ToolKit (GATK) (115,116). Inaccurate / biased base quality scores
were recalibrated using the BaseRecalibrator, the AnalyzeCovariates and the
PrintReads walkers of GATK, which use machine learning to model these errors
empirically and adjust the quality scores accordingly. Alignment statistics for each
sample were calculated on the “clean” sample BAM files.
4.2.5. Variant Discovery and Quality Filtering: The pre-processing steps were
followed by variant calling using the HaplotypeCaller walker of GATK on each sample
BAM file. Variant sites are identified by taking into account the haplotype likelihood
predicted by building Dr. Brujin-like graphs in regions where the data displays variation
relative to the hg19 reference genome. This step is also guided using the dbSNP, and
Mills and 1000G gold standard SNP and indel databases. The output is a set of
unfiltered/raw SNP and indel calls in the Genomic Variant Call Format (gVCF) file.
Sample-specific gVCFs were merged into a single VCF file and a cohort-wide joint
genotyping was performed using the CombineGVCFs walker of GATK. Finally, Variant
Quality Score Recalibration (VQSR) was performed to assign the statistical probability
to each variant call and produce a call-set distilled to a desired level of truth sensitivity.
The raw SNP call-set was filtered using the GATK VariantFilter module, with variants
required to pass the following criteria – “QUAL >= 30” AND “DP >= 25”. The raw indel
call-set was filtered with variants required to pass the following criteria – “QD > 2.0”
AND “FS < 200.0” AND “InbreedingCoeff > -0.8” AND “ReadPosRankSum > -20.0".
4.2.6. Annotation and Filtering for Genes and Variants of Interest: SnpEff was used
for annotating the functional effects of high-quality SNPs and INDELs on genes,
transcripts and protein sequences including: a) their genomic location (i.e., intron, 5’ or
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3’ untranslated region, upstream/downstream of a transcript, or intergenic region); b)
their consequence on protein sequence (i.e., stop-gained, missense, frameshift); c)
known variants from dbSNP (117), ClinVar

(118), and the 1000 Genomes Project

(119).
A total of sixteen candidate genes were selected for investigation of rare variants based
on their involvement in the extra-cellular matrix (ECM) composition and synthesis and
previously linked to connective tissue disorders such as classical types of Ehlers-Danlos
syndrome (types I and II) as well as Ehler’s-Danlos Syndrome types VIIA and VIIB,
osteogenesis imperfecta type II and restrictive dermopathy (106). These genes encode
for major ECM components including fibrillar collagens (COL1A1, COL1A2, COL2A1,
COL3A1, COL5A1, COL5A2) and associated proteins (CRTAP, ELN) as well as
enzymes involved in collagen processing and ECM production (ADAMTS2, BMP1,
LEPRE1, LOX, LOXL1, SERPINH1, ZMPSTE24, FKBP10). Further analyses were
focused on variants affecting only coding regions of the selected genes to best identify
functional variation and this included nonsense, frameshift, splice site and damaging
missense variants. Damaging missense variants were selected on the basis of most
deleterious predictions in both Polyphen2 (HumDiv - probably damaging) as well as
SIFT (damaging) platforms. When multiple isoforms were identified, only variants with
the most deleterious damaging predictions for all isoforms were included.
4.2.7. Custom Genotyping: The variants identified and selected for further analysis
from Whole Exome Sequencing (Table 4.2) were validated and additional samples (an
independent cohort of additional 188 cases and 175 controls) were genotyped for the
selected variants. Genotyping was performed on the Agena (previously Sequenom)
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MassArray iPLEX platform following manufacturer’s instructions (120) at the University
of Minnesota Genomics Center.
4.2.8. Testing for Genetic Association: The combined set of variants identified in the
initial WES and by additional genotyping were tested for genetic association using the
combined Optimized Sequence Kernel Association Test (SKAT-O) software package in
R version 3.2.3 (121–123) with default parameters adjusting for small sample size and
ancestry estimates as covariates. A burden test was selected because the variants
under study were rare (variant frequency in sample set < the calculated fixed frequency
threshold T = 0.034), in the coding region and known/ expected to alter amino acid
sequence and thus assumed to contribute to risk with same direction if effect (124).
4.2.9. Statistical Analysis: Mean levels of demographic variables were tested using a
2-tailed Student’s t-test. Count data (for gravidity and parity) was square-root
transformed before performing tests. P-values < 0.05 were considered statistically
significant.

4.3. Results
4.3.1. Study Population: The characteristics of the subjects used in the study are
presented in Tables 4.1.A and 4.1.B. There were no significant differences in maternal
age, gravidity and parity between the cases and controls. As expected, the pregnancies
complicated by PPROM had a significantly shorter gestational age at delivery than the
term pregnancy control group (p < 0.001) and the PPROM neonatal birth weights were
also significantly lower (p < 0.001) for both sample sets. Individual neonatal genetic
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ancestry estimates were calculated and used to compare the ancestry proportions
between cases and controls and no differences were found. (Appendix, Table A.4.1)
4.3.2. Variant Discovery: The analysis of WES was focused on damaging mutations
(non-sense and frameshift mutations) and predicted damaging missense variants as
identified by SIFT and Polyphen2 in the preselected genes of interest in neonatal DNA
derived from of 49 pregnancies complicated by PPROM and 20 normal term
pregnancies.
4.3.3. Variants Identified in Genes involved in ECM Components and ECM
Synthesis: The variants identified in the selected genes of interest in the initial WES
are described in Table 4.2. The position-specific annotation of the variant in the protein
(“within feature” column) describes the molecular processing outcome of that particular
region in the final protein product. An additional 188 cases and 175 controls were
genotyped for these variants.
In the discovery WES, all variants identified were unique to cases. A heterozygous
nonsense mutation in BMP1 (rs116360985), an enzyme involved in procollagen
processing, was discovered in 1 PPROM case. This mutation truncates the protein at
amino acid residue 721 in a protein that has an isoform of 730 amino acids, so the
functional significance is not clear. A frameshift mutation (rs137853883) in the FKBP10
gene, which encodes for a chaperone protein involved in ECM metabolism, was
identified in 1 case. Heterozygous predicted damaging (Polyphen2 and SIFT) missense
variants were found in COL1A2; rs139528613 in 3 cases and rs145693444 in 2 PPROM
cases. Predicted damaging heterozygous missense variants were found in COL5A1
(rs2229817, rs116003670 and rs61739195) in 3 different PPROM cases.
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Although

rs61739195 and rs2229817 are predicted to be damaging by both Polyphen 2 and
SIFT, these variants are listed to be benign in ClinVar.

All other mutations and

missense variants are listed as having unknown clinical significance.
Interestingly, two missense variants, rs201234519 and rs78690642, both predicted to
be damaging by Polyphen2 and SIFT were identified in COL2A1, which encodes a
fibrillar collagen found in cartilage and tendons, and not previously thought to be
expressed in amnion. Rs78690642 was present in 5 cases and rs201234519 was
present in one different case with none of the controls having either of the two variants.
We performed an RT-PCR on RNA extracted from fetal membranes from normal term
pregnancies (n = 6) using COL2A1 specific primers, and obtained a robust amplicon
that was sequence-verified to be COL2A1 mRNA (Appendix, Figure A.4.1). Thus, it is
possible that COL2A1 mRNA, and possibly protein, is expressed in fetal membranes,
and this has been overlooked in previous studies.
None of the heterozygous variants in the COL1A2, COL2A1 and COL5A1 genes
appeared in the same subject. However, one case had a predicted damaging mutation
in COL1A2 (rs139528613) as well as a nonsense mutation in BMP1 (rs116360985).
Missense variants that were not predicted to be damaging using our stringent criteria
were found in the fibrillar collagen genes as well as genes involved in their synthesis
(Appendix, Table A.4.2). A number of these variants were novel and only detected in
cases. In some instances one of the predictive algorithms suggested that the variant
was potentially damaging (e.g., rs201944190), but their significance with respect to
PPROM remains to be evaluated.
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Observed allele frequencies for both the initial WES as well as the follow up study are
shown in Table 4.3. In total, WES identified 7 predicted to be damaging missense
variants in the candidate genes involved in ECM formation in 14 cases, one frameshift
variant in FKBP10 and one nonsense mutation in BMP1 in one case each and none in
the 20 controls. In addition, the follow-up study revealed an increased burden of the
damaging missense variants in 10 additional cases and 6 controls. The nonsense
mutation in BMP1 was identified in an additional 4 cases and 5 controls and the
frameshift variant in FKBP10, was not found in any of the additional samples
genotyped. Combining the two sample sets revealed an increased frequency of the risk
allele in cases as compared to controls.
4.3.4. Genetic Association Analysis: To determine if the rare variants collectively
contributed to PPROM risk, we performed a genetic burden test using the combined
initial WES and follow up genotypes including adjustment for West African ancestry.
The omnibus SKAT-O test yielded a significant association for the rare variants with
PPROM (p-value = 0.0225).
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Table 4.1.A. Characteristics of the study population in the initial WES set
Cases (n = 49) and Controls (n = 20) were compared for key patient characteristics.
Values represent means with SDs reported in parentheses for each group.
Cases

Controls

Mean (SD)

Mean (SD)

Maternal Age (years)

27.57 (5.67)

25.8 (4.86)

0.198

Gestational Age at Delivery (weeks)

29.59 (4.17)

38.55 (1.19)

< 0.001

Neonatal Weight (kgs)

1.47 (0.65)

3.21 (0.53)

< 0.001

Gravidity

1.73 (0.54)

1.78 (0.48)

0.685

Parity

0.85 (0.72)

1.04 (0.62)

0.280

Characteristic

p-value

Table 4.1.B. Characteristics of the study population used for follow-up
genotyping.
Cases (n = 188) and Controls (n = 175) were compared for key patient characteristics.
Values represent means with SDs reported in parentheses for each group.
Cases

Controls

CCCharacteristic

p-value
Mean (SD)

Mean (SD)

Maternal Age (years)

26.76 (5.91)

26.6 (6.02)

0.798

Gestational Age at Delivery (weeks)

31.05 (3.63)

39.47 (0.10)

< 0.001

Neonatal Weight (kgs)

1.7 (1.07)

3.35 (0.31)

< 0.001

Gravidity

1.91 (0.59)

1.89 (0.58)

0.09

Parity

1.06 (0.77)

1.10 (0.69)

0.62
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Table 4.2. Variants identified in genes involved in ECM composition and
synthesis The positional and putative functional impact of the variants identified in the
initial WES (unique to cases in the WES) in the selected genes of interest and selected
for additional genotyping are shown. (PPD: Propeptide = part of a protein that is cleaved
during maturation or activation, chain = extent of polypeptide chain in the mature
protein).
Allele
Gene

SNP ID

Location

Type
Change

BMP1

rs116360985

FKBP10

rs137853883

COL1A2

rs139528613

COL1A2

AA Position
(Residue
Change)

Within
Feature

C>T

Nonsense

721 (R > Ter*)

Chain

->C

Frameshift

278 (G > R)

Chain

Chr7: 94028386

G>A

Missense

41 (R > H)

PPD

rs145693444

Chr7: 94038721

G>T

Missense

294 (V > F)

Chain

COL2A1

rs201234519

Chr12:48391685

G>T

Missense

64 (P > H)

PPD

COL2A1

rs78690642

Chr12:48367327

C>T

Missense

1374 (G > S)

Chain

COL5A1

rs116003670

Chr9:137582842

G>A

Missense

65 (R > Q)

Chain

COL5A1

rs2229817

Chr9:137726950

C>T

Missense

1757 (T > M)

PPD

COL5A1

rs61739195

Chr9:137708884

C>T

Missense

1379 (P > S)

Chain

Chr8: 22058684

Chr17:39975558
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Table 4.3. Allele frequencies of the variants identified
The table shows the allele frequencies of the putative risk allele (RAF) of variants listed
in Table 4.2 in the general populations of CEU - Northern Europeans from Utah
(European-American), AFR –African (combined African populations) and ASW –
Americans of African ancestry in Southwest USA (admixed African Americans)
ancestries as reported in the 1000 Genomes Project [50] and their observed risk allele
frequencies in the initial WES and in the follow up study on an independent sample
cohort used for custom genotyping, separate and combined. Please note that the AFR
allele frequencies constitute a super population, which includes the allele frequencies
from all African populations in the 1000 Genomes Project including the ASW.

SNP ID

RAF in

RAF in

RAF in

RAF in

CEU/AFR/ASW

Initial WES

Follow-Up

Combined

(1000 genomes)

Case/ Control

Case/ Control

Case/ Control

0.011/ 0.014

0.011/ 0.013

0/ 0

0.002 / 0.00

rs116360985

0.000/0.005/ 0.000

rs137853883

NA

rs139528613

0.000/0.011/ 0.025

0.031/ 0

0.006/ 0.009

0.011/0.008

rs145693444

0.000/0.004/ 0.008

0.02/ 0

0/ 0

0.004/ 0

rs201234519

0.000/0.002/ 0.000

0.01/ 0

0.006/ 0

0.006/ 0

rs78690642

0.000/0.014/ 0.025

0.05/ 0

0.009/ 0.003

0.018/ 0.003

rs116003670

0.000/0.007/ 0.000

0.01/ 0

0.006/ 0.006

0.006/ 0.005

rs2229817

0.000 /0.001/ 0.008

0.01/ 0

0.003/ 0

0.004/ 0

rs61739195

0.005 /0.000/ 0.000

0.01/ 0

0/ 0

0.002/ 0

0.01/ 0
0.01/ 0
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4.4. Discussion
The present study using WES to identify mutations and damaging variants in the
neonatal genome associated with PPROM supported the working hypotheses that rare
variants could be significant contributors to preterm birth, particularly mutations or
variants that would alter ECM integrity, resulting in weaker fetal membranes or
increased susceptibility of ECM proteins to proteolytic enzymes.
Crosslinked networks of several collagen types constitute the major components of the
ECM of the fetal membranes. Altered expression patterns or altered metabolism of any
of the ECM or collagen components could lead to a loss of integrity of the fetal
membranes (105,106). Some studies have shown that PPROM membranes have an
altered amnion collagen content as compared to normal term pregnancies (125–127).
We anticipated identifying variants that would disrupt the ECM, and looked for mutations
and variants in genes encoding proteins involved in the production of the major ECM
proteins in fetal membranes, especially variants that would alter the collagen content or
structure of the amnion. With the exception of BMP1 and FKBP10, we discovered no
damaging mutations (nonsense, frameshift, splice junctions) in the selected genes of
interest. BMP1 is a metalloproteinase involved in collagen processing. FKBP10 codes
for a chaperone protein, FKBP65, which is known to be associated with the extracellular
matrix protein - tropoelastin. Mutations in FKBP10 have been found in several family
members with osteogenesis imperfecta and clinical consequences of these mutations,
one of which is the frameshift mutation identified in our study (rs137853883), included
loss of FKBP65 protein function leading to delayed type I procollagen secretion and
improper crosslinking of collagen (128,129).
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The tensile strength of fetal membranes is determined by the assembly of fibrillar
collagens (I, III, V) into fibrils. The size of the fibrils is mainly determined by type V
collagen in association with types I and III collagens and proteoglycans (105,130). Both
COL5A1 and COL5A2 are involved in the production of type V collagen, which
participates in early fibril initiation, determination of fibril structure and matrix
organization (131,132). Type I collagen is involved in fibril formation and consists of two
alpha-1 chains (COL1A1) and one alpha-2 chain (COL1A2). Mutations in the COL1A1
and COL1A2 genes are known to cause rare forms of Ehler’s Danlos Syndromes, types
VIIA and B and osteogenesis imperfecta types I and II (106,133,134). Mutations in
COL5A1 and COL5A2 genes resulting in haploinsufficiency or structural modifications of
type V collagen are common causes for classical Ehler’s Danlos Syndrome (types I and
II) (135). These disorders have been associated with increased risk of PPROM when
the fetus/neonate is affected (106,107,109). A case-control study with case-parent
triads and case-mother dyads suggested a significant association of COL5A1
(combined fetal-maternal association) and COL5A2 (fetal association) with spontaneous
preterm birth (131). Our study identified several predicted to be damaging missense
variants in the COL1A2 and COL5A1 genes that were unique to only cases in the initial
WES. Missense variants were identified in the COL1A1, COL3A1 and COL5A2 genes
but their predicted impact on protein function was benign.
Potentially damaging missense variants in the COL2A1 gene were also discovered with
increased frequency in PPROM cases. COL2A1 codes for cartilage collagen and until
now there has been no evidence of COL2A1 expression in the amnion making the
significance of this finding uncertain (136).
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However, human amniotic membranes

(HAM) have been used as a source of stem cells for chondrocyte culture, where
chondrocytes grown on the chorionic side of the HAM express type II Collagen
(137,138). RT-PCR using mRNA from fetal membranes (amnion) obtained from normal
term pregnancies and COL2A1 specific primers, revealed detectable COL2A1 mRNA
expression, raising the possibility of low levels of expression of COL2A1 protein that
might play a significant role in fetal membrane integrity. Alternatively, the detected RNA
could be generated from illegitimate transcription of the COL2A1 gene. The putative
functional significance of the variants could be due to variants in genes that are in
linkage disequilibrium with the COL2A1 SNPs or they could have a disrupting impact on
overlapping coding sequences on the DNA strand opposite the COL2A1 gene. A
noncoding RNA (LOC105369752) of unknown function does reside there. There was no
linkage disequilibrium (LD) information available for rs201234519. Rs78690642 is in LD
with three other SNPs in the COL2A1 gene (rs1455684563, rs76519927 and
rs2071358).
It is important to note that there are significant disparities in the prevalence rates of
PPROM with African-American women experiencing a 2-fold increased risk of PPROM
as compared to European-American women. This disparity cannot be explained by
socio-economic factors alone and genetic variation and gene-environment interactions
are involved (49,50). Most of the rare variants described in this study are more
prevalent in individuals of West African descent than European descent in the general
population. Interestingly, this is also true for the SERPINH1 promoter SNP that has
previously been associated with PPROM (110). Admixed populations such as the
African Americans have varying proportions of West African and European genetic
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ancestry contributions across individuals and also differences in groups across different
regions within the US (139,140). Even though the sample set in our initial WES and the
independent sample set on which custom genotyping was performed consist of
individuals from two different regions, Richmond and Detroit respectively, the fact that
their combined SKAT-O gives a significant association is promising, suggesting a higher
functional impact of the rare variants identified. Moreover, the fact that the combined
burden of rare variants, which are of African origin (all except rs61739195), is
significantly associated with increased PPROM risk suggests that the increased
prevalence of PPROM in African-American populations is partly attributed to these rare
population-specific alleles.
There are potentially other rare variants inactivating transcription factors or disrupting
transcription factor binding sites that might result in reduced production of fibrillar
collagens in the amnion. These were not explored in our study, nor were epigenetic
factors that could influence collagen gene expression.

These should be explored in

future research. Conversely, variants that affect expression of matrix degrading
enzymes, particularly the matrix metalloproteinases, could contribute to PPROM
risk. This has been suggested by association studies with promoter variants in the
MMP1, MMP8, and MMP9 genes (141–143).
In summary, using a screen to detect deleterious genetic variants that could promote
PPROM in pregnancies hosted by women of African-American descent, we discovered
evidence that rare damaging non-sense and frameshift mutations and predicted to be
damaging missense variants in a variety of genes involved in negatively modulating the
ECM metabolism-related genes are more prevalent in neonates born from pregnancies
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complicated by PPROM than normal term pregnancies. Despite sample size being a
limitation in our study, the variants identified strongly suggest that the fetal contribution
to PPROM is polygenic and driven by multiple rare rather than common genetic variants
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Chapter 5: Expression Patterns of the Chromosome 21 MicroRNA Cluster (miR99a, miR-125b and let-7c) in Chorioamniotic Membranes.

Please note: This chapter is accepted for publication in Placenta as
Bhavi Modi, Sonya Washington, Scott W. Walsh, Colleen Jackson-Cook, Kellie J.
Archer, Jerome F. Strauss, III. Expression Patterns of the Chromosome 21 MicroRNA
Cluster (miR-99a, miR-125b and let-7c) in Chorioamniotic Membranes.

Abstract
Trisomy 21 (T21) is the most common chromosome abnormality in humans and is
associated with a spectrum of phenotypes, including cognitive impairment, congenital
heart defects and immune system defects. In addition, T21 is also associated with
abnormalities of fetal membranes including chorioamniotic separation, delayed fusion of
the chorioamniotic membranes, defects in syncytiotrophoblast formation, as well as
amniocyte senescence. There is evidence indicating miRNAs encoded by sequences
on chromosome 21 (Chr-21) are involved in several of the cognitive and neurological
phenotypes of T21, but the role of Chr-21 derived miRNAs in fetal membrane
abnormalities associated with T21 has not been investigated. In the current study, we
determined the expression patterns of three miRNAs derived from a cluster on Chr-21 –
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hsa-miR-99a, hsa-miR-125b and hsa-let-7c in chorioamniotic membranes obtained from
term pregnancies with spontaneous rupture (n = 20). Tissue and location specific
expression patterns within the chorioamniotic membranes were identified. The rupture
zone in the choriodecidua had distinct expression patterns compared to other fetal
membrane locations. Despite the increased gene dosage associated with T21, the
expression of all three miRNAs was reduced in cultured T21 amniocytes as compared
to cultured euploid amniocytes. In silico analysis of experimentally validated targets of
the three miRNAs suggest these Chr-21 derived miRNAs play a potential role in fetal
membrane rupture and the fetal membrane defects associated with T21.

5.1. Introduction
Trisomy 21 (T21) is associated with abnormalities of the fetal membranes, including
chorioamniotic separation and delayed fusion of the amnion and chorion (144–146).
Cytotrophoblast abnormalities and early amniocyte senescence have also been
reported (147,148). Early senescence of fetal extraembryonic tissues has been
proposed to contribute to preterm birth (149). The underlying pathophysiological
explanations for these abnormalities have not been elucidated. Epigenetic alterations in
the chorion and amnion (differential DNA methylation) have been reported, raising the
possibility that both chromosome dose, as well as epigenetic factors, contribute to
dysfunction associated with cells in the fetal membranes (150).
MicroRNAs (miRNAs) are small (20-24 nucleotides) single-stranded, noncoding,
regulatory RNA molecules. They are involved in post-transcriptional regulation of gene
expression either by complimentary binding to the 3’ untranslated region of their target
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mRNA, thereby inhibiting translation or inducing mRNA degradation (61,62).

Altered

expression of microRNAs, including those encoded on chromosome 21 (Chr-21), are
thought to contribute to the phenotypes associated with T21 (151,152). However, the
role of these miRNAs in the fetal membrane abnormalities associated with T21 has not
been studied in detail. We examined the pattern of expression of a cluster of Chr-21
microRNAs that are potential candidates for altering fetal membrane function in T21.
We determined the relative levels of expression of the 3 microRNAs in this cluster in the
amnion and choriodecidua, as well as differences in expression in different locations
within the fetal membranes. Examination of in vitro cultured amniocytes from normal
pregnancies and pregnancies hosting a T21 fetus revealed that T21 is associated with
reduced expression levels of these three microRNAs. Based on the known roles of
these microRNAs in the epigenetic control of gene expression, some of the fetal
membrane structural defects and cellular abnormalities associated with T21 could be
explained by altered expression of this microRNA cluster.

5.2. Materials and Methods
5.2.1. Study Population: Self-reported African-American women admitted at MCV
Hospitals, Richmond, VA, with spontaneous labor at term (defined as more than 37
weeks of gestation) with rupture of membranes (n = 20) were recruited for the study.
Women with multiple gestations, fetal anomalies, connective tissue diseases and
pregnancy complications requiring induction of labor were excluded. Fetal membrane
specimens were collected as described below from 12 male and 8 female fetal subjects
delivered from 20 term pregnancies.
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In order to test the effect of gene dosage on the expression of the Chr-21 localized
miRNA cluster that were assessed in this study, cultured amniocyte specimens from
local cell repository of cryopreserved specimens were evaluated from fetuses (race
unknown) with a T21 complement (n = 7; T21 cases) or a disomic chromosomal
complement (n = 6; controls). Fetal sex of the amniocyte cultures were as follows: T21
cases (2 males, 5 females); euploid controls (4 males, 2 females).
The study was approved by the Institutional Review Board of MCV Hospitals,
Richmond, VA. Written informed consent was obtained from the patients before
collection of samples.
5.2.2. Collection of samples: Human placentas and fetal membranes were obtained at
the time of vaginal delivery or when C-section was performed at term. Fetal membranes
specimens were collected within 1-2 hours of delivery. After visual identification of the
rupture zone (Figure 5.1) as done previously by Nhan-Chang et al (153),

the two

adherent fetal membranes (amnion and choriodecidua) were separated/ teased apart
from the rupture tear line. A piece of membrane tissue (~ 2cm2) spanning the rupture
site was dissected sharply from both the amnion as well as the choriodecidua,
constituting the rupture zone amnion (RZA) and rupture zone choriodecidua (RZC)
samples, respectively. The two membranes were continuously teased apart and pieces
of both the amnion and choriodecidua were dissected at the mid region, which was
halfway between the rupture site and the placenta, followed by at the peri-placental
region, which is adjacent to the placenta. This method yielded a set of 6 specimens
from each patient: 1) amnion from the rupture zone (RZA), 2) choriodecidua from the
rupture zone (RZC) (3) amnion from the mid-region (MRA), 4) choriodecidua from the
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mid-region (MRC), 5) amnion from the peri-placental region (PPA), 6) choriodecidua
from the peri-placental region (PPC).
The amniocytes from T21 cases and euploid controls (defined above) were established
in culture (monolayer cultures in flasks), propagated in vitro (1 – 3 passages), and
cryopreserved using standard techniques (154,155). The frozen cell aliquots were
retrieved and maintained on ice prior to RNA isolation, which was accomplished as
described below. The amniocyte cultures constitute a mixed population of fibroblast
cells, amniotic fluid cells (derived from fetal membranes and trophoblasts) and epithelial
cells (derived from epithelial fetal skin, bladder and other epithelia). The tissue culture
procedure selects for growth of fibroblast-like cells, followed by amniotic fluid cells and
epithelial cells with decreasing proliferative capacity in culture respectively (155).
5.2.3. RNA isolation and miRNA qPCR: For the miRNA-qPCR assays, total RNA was
extracted using miRVana miRNA isolation kit (Ambion Life Technologies) following the
manufacturer’s protocol. MicroRNA qPCRs were performed using the TaqMan
MicroRNA Assays (Life Technologies) following the manufacturer’s instructions. Briefly,
10ng RNA was reverse transcribed using the target (miRNA) specific stem-loop RT
primer and the TaqMan MicroRNA reverse transcription kit. The cDNA was then
amplified by real-time qRT-PCR using target specific TaqMan primer-probe mix. The
qRT-PCR was performed in triplicates per sample. Different small RNAs (RNU48,
RNU43 and miR-16) were tested for consistent expression across all samples and
RNU48 was selected for normalization of the qRT-PCR expression data. The mean
expression value for each miRNA was divided by the mean RNU48 expression value to
normalize each sample.
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5.2.4. Statistical analysis: For miRNA qPCR assays in amniocyte samples from T21
cases and controls, normalized qPCR expression values for the three miRNAs (hsamiR-99a, hsa-miR-125b and hsa-let-7c) were log2 transformed and used for student’s ttest for determining statistical significance (P < 0.05).
For miRNA expression analysis in the fetal membranes normalized expression values
from qPCR for the three miRNAs (hsa-miR-99a, hsa-miR-125b and hsa-let-7c) from the
6 specimens collected for each of the 20 participating subjects were log2 transformed
prior to statistical analysis. For each miRNA, a random coefficient mixed effects model
predicting log2 expression was fit, including the location/tissue factor variable as a fixed
effect and subject as a random effect (156). Linear contrasts from the mixed effects
model were constructed to test the following: MRA versus MRC; PPA versus PPC; RZA
versus RZC; MRA versus PPA; MRA versus RZA; PPA versus RZA; MRC versus PPC;
MRC versus RZC; PPC versus RZC; and Amnion versus Choriodecidua. Adjusted pvalues are reported for the linear contrasts using the single-step method (p < 0.05 was
considered significant) (157).
To compare male and female fetal subjects with respect to miRNA log2 qPCR
expression, Welch’s t-test was performed for each miRNA (let-7c, miR-125b and miR99a), location (MR, PP, RZ and VP) and tissue (Amnion, Choriodecidua), adjusting for
possible unequal variances between the groups. A Bonferroni correction was used to
control for multiple comparisons and an adjusted alpha level of 0.0071 or below was
considered significant (157).
All statistical analyses were performed in the R programming environment (121).
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5.2.5. MicroRNA target identification and pathway analysis. The miRNA target
prediction filter in Qiagen’s Ingenuity® Pathway Analysis tool (IPA®, QIAGEN Redwood
City, www.qiagen.com/ingenuity) was used to identify potential target genes for hsamiR-125b, hsa-miR-99a and hsa-let-7c. Pathway analysis was performed in IPA on
target genes with experimentally observed interactions with the miRNAs.
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Figure 5.1. Sites of tissue collection
The placenta with the fetal membranes showing the representative sites of tissue
collection by region i.e. gross sites for the membrane rupture called the Rupture Zone
(RZ), Mid-Region (MR) and the Peri-placental (PP) regions.

For RZ, MR and PP

regions tissues were collected from both the amnion (A) and the choriodecidua (C)
separately.
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5.3. Results
5.3.1. Trisomy impacts expression of the Chr21Orf34 microRNA cluster: The qPCR
miRNA expression assays that were completed on cultured amniocytes revealed
significant differences (p < 0.05) in the expression of all three miRNAs between the T21
cases (n = 7) compared to disomic controls (n = 6), with reduced expression levels in
T21 amniocytes. For each miRNA, dot-plots of log2 expression (normalized by RNU48)
by case and control are presented in Figure 5.2.
5.3.2. Differential miRNA expression patterns are observed between the amnion
and the choriodecidua and at different locations within the choriodecidua: For
each miRNA, normalized qPCR expression values for all samples (n = 20) were log2
transformed for each of the location/ tissue types and used for statistical analysis. QPCR results are shown in Figure 5.3. The differences and adjusted p-values for linear
contrasts from the random coefficient mixed effects model for all pairwise comparisons
are reported in Table 5.1 and visually displayed in Figure 5.4. Comparisons between the
amnion and the choriodecidua at different locations revealed that all three miRNAs had
significant expression differences at the rupture zone. For the non-rupture sites, for
miR99a and let-7c there were significant expression differences at the mid-region,
whereas miR-99a and miR-125b were differentially expressed between the amnion and
the choriodecidua at the peri-placental region. None of the three miRNAs had significant
differences at any location within the amnion. Comparatively, the choriodecidua showed
significant differences (lower abundance) between the rupture zone and non-rupture
sites, with all three miRNAs showing significant lower abundances between the rupture
zone and the peri-placental region, and miR-99a and let-7c showing significant
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differences (lower abundance) between the rupture zone and the mid-region
choriodecidua as well.
5.3.3. MiRNA Correlation in amnion and the choriodecidua by location: Pearson’s
correlation was used to examine the strength of linear relationship (pairwise) between
the log2 expression of the three miRNAs by location for amnion (Table 5.2) and for the
choriodecidua (Table 5.3). All pairwise miRNA relationships in all 3 locations in the
amnion as well as the choriodecidua were positively correlated, though the strength of
correlation (determined by ρ) varied with specimen tissue/ site. For the periplacental
region, all pairwise miRNA comparisons showed significant correlations (P < 0.05) for
both the amnion and the choriodecidua. Other significant pair-wise correlations in
expression between miRNAs were observed in the choriodecidua at the mid-region (let7c and miR-125b) and at the rupture zone (let-7c and miR-125b, as well as miR-99a
and miR-125b) with miR-99a and miR-125b showing a strong correlation (ρ > 0.5) at
this site.
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(Fig. 5.2.A)

(Fig. 5.2.B)
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Figure 5.2 MiRNA Expression in Amniocytes
Significant differences (p < 0.001) in miRNA expression were observed between T21
case (n = 7) and disomic control (n = 6) amniocyte samples for hsa-miR-let7c (A), hsamiR-125b (B) and hsa-miR-99a (C).
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(Fig. 5.3.A)

(Fig. 5.3.B)

(Fig. 5.3.C)

Figure 5.3. MiRNA Expression in Fetal Membranes
qPCR results for log2 expression of hsa-let-7c (A), hsa-miR-125b (B) and hsa-miR-99a
(C) for each group/site of collection are shown. (PP=Periplacental, MR=MidRegion,
RZ=Rupture Zone; A = Amnion/C = Choriodecidua). (Sample N = 20). Data are
represented as Mean ± Standard Error (*P < 0.001, **P = 0.002, ***P<0.05)
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(Fig. 5.4.A)
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Figure 5.4. Comparison of miRNA expression by tissue and location. Dot-plot of
log2 expression for hsa-let7c (A), hsa-miR-125b (B) and hsa-miR-99a (C) are shown for
each specimen collection location, separated by amnion (left) versus choriodecidua
(right). Each subject’s observations are connected with a line.
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Table 5.1. Pairwise comparisons of miRNA expression by tissue and location
The differences (log2 contrast estimates) and adjusted p-values for linear contrasts from
the random coefficient mixed effects model for all pairwise comparisons are shown for
hsa-let7c, hsa-miR-125b and hsa-miR-99a. (P < 0.05, considered significant, shown in
bold)
Let-7c Estimate

miR-125b Estimate

miR-99a Estimate

(Adjusted p-value)

(Adjusted p-value)

(Adjusted p-value)

MRA vs. MRC

0.8127 (<0.001)

0.5421 (0.1222)

1.3674 (<0.001)

PPA vs. PPC

0.8161 (0.0873)

1.0005 (0.0331)

1.3056 (<0.001)

RZA vs. RZC

1.6851 (<0.001)

1.0628 (<0.001)

1.5455 (<0.001)

A vs. C

1.1046 (<0.001)

0.8685 (<0.001)

1.4062 (<0.001)

MRA vs. PPA

-0.1980 (0.961)

-0.70407 (0.0643)

-0.1492 (0.9879)

MRA vs. RZA

0.2743 (0.287)

0.01895 (1.0000)

0.2807 (0.2066)

PPA vs. RZA

0.4722 (0.648)

0.72302 (0.3538)

0.4299 (0.5728)

MRC vs. PPC

-0.1945 (0.638)

-0.24567 (0.3453)

-0.2110 (0.4481)

MRC vs. RZC

1.1466 (<0.001)

0.53970 (0.0757)

0.4588 (0.0027)

PPC vs. RZC

1.3412 (<0.001)

0.78537 (0.0024)

0.6698 (<0.001)

Comparison
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Table 5.2. Pairwise Pearson’s correlation for log2 miRNA expression by location
for amnion. The strength of linear relationship (pairwise) between the log2 expression
of the three miRNAs in the amnion by location is shown. Values represent Pearson’s
coefficient of correlation (ρ) with estimated p-values in parentheses.

(P < 0.05

considered significant, shown in bold)
Periplacental

MidRegion

Rupture Zone

ρ (p-value)

ρ (p-value)

ρ (p-value)

let-7c & miR-99a

0.627 (0.003)

0.255 (0.28)

0.407 (0.07)

let-7c & miR-125b

0.560 (0.01)

0.209 (0.38)

0.029 (0.90)

miR-99a & miR-125b

0.541 (0.01)

0.291 (0.21)

0.336 (0.15)

Comparison

Table 5.3. Pairwise Pearson’s correlation for log2 miRNA expression by location
for the choriodecidua. The strength of linear relationship (pairwise) between the log2
expression of the three miRNAs in the choriodecidua by location is shown. Values
represent Pearson’s coefficient of correlation (ρ) with estimated p-values in
parentheses. (p < 0.05 considered significant, shown in bold)
Periplacental

MidRegion

Rupture Zone

ρ (p-value)

ρ (p-value)

ρ (p-value)

let-7c & miR-99a

0.469 (0.04)

0.445 (0.05)

0.383 (0.10)

let-7c & miR-125b

0.514 (0.02)

0.495 (0.03)

0.453 (0.04)

miR-99a & miR-125b

0.665 (0.001)

0.362 (0.12)

0.646 (0.002)

Comparison
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5.3.4. Pathway analysis of genes targeted by miRNAs: MicroRNA target prediction
filter in IPA identified a total of 217 experimentally observed miRNA-target gene
interactions for all three miRNAs. The 212 target genes from these interactions were
used for core pathway analysis in IPA to identify pathways, diseases & bio-functions
and networks that are “over-represented” in target genes of the Chr-21 microRNA
cluster. The key findings from the pathway analysis are shown in Table 5.4. Of note,
several of the functional annotations suggest involvement of cell survival, cell death and
cellular development pathways (molecular mechanisms of cancer), which play a role in
fetal membrane rupture. In addition, a significant number of targeted genes overlap with
the categories of reproductive system disease (101 genes) and developmental disorder
(45 genes), which also have a strong association with preterm birth, as well as T21. The
top network (Figure 5.5), based on the functional annotations of the target genes, had
26 focus molecules (26 of the 212 target genes) and IPA Network Score = 48. The
associated network functions involving the cell cycle, connective tissue development
and function, and cancer. All of these functions have been shown to have strong
correlations with membrane rupture and/ or phenotypic traits associated with Down’s
syndrome.
5.3.5. Fetal gender and miRNA expression: Fetal gender is known to be associated
with adverse pregnancy outcomes (158,159). Male (n = 12) and female (n = 8) fetal
subjects in the study were compared with respect to miRNA expression (log2 qPCR
estimates) for each miRNA for each of the 6 groups or sampling sites. Only let-7c in
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mid-region choriodecidua samples was significantly different (p < 0.0071) when
comparing fetal gender. (Appendix, Tables A.5.1 – A.5.3)
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Table 5.4. Ingenuity pathway analysis of the genes targeted by hsa-miR-99a, hsamiR-125b and hsa-let-7c. Key findings from the pathway analysis (performed in IPA)
of the 212 genes targeted by the three miRNAs in the Chr21 cluster are described. The
Top Canonical Pathways (5.4.A), Top Diseases and Disorders (5.4.B), Top Molecular
and Cellular Functions (5.4.C) and Physiological System Development and Functions
(5.4.D) over-represented in the target genes are shown.
5.4.A: Top Canonical Pathways
Name
Bladder Cancer Signaling
Chronic Myeloid Leukemia Signaling
Glioblastoma Multiforme signaling
Colorectal Cancer Metastasis Signaling
Molecular Mechanisms of Cancer

p-value
1.04E-09
5.26E-10
4.18E-13
3.80E-09
3.61E-12

Overlap
12.60%
11.50%
10.70%
6.50%
6.10%

5.4.B: Top Diseases and Disorders
Name
Organismal Injury and Abnormalities
Cancer
Reproductive System Disease
Tumor Morphology
Developmental Disorder

p-value
3.7E-07 - 3.82E-18
3.7E-07 - 3.82E-18
3.7E-07 - 5.73E-15
2.02E-07 - 3.85E-17
3.68E-07 - 2.88E-14

No. of gene
153
151
101
51
45

p-value
3.70E-07 - 1.34E-20
3.70E-07 - 1.34E-20
3.32E-07 - 5.40E-18
3.10E-07 - 3.43E-13
3.70E-07 - 2.93E-16

No. of genes
125
112
110
70
64

5.4.C: Top Molecular and Cellular Functions
Name
Cellular Growth and Proliferation
Cellular Development
Cell Death and Survival
Cellular Movement
Cell Cycle
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5.4.D: Physiological System Development and Function
Name
Organismal Development
Organismal Survival
Tissue Morphology
Hematological System Development and Function
Lymphoid Tissue Structure and Development
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p-value
3.31E-07 - 1.03E-17
5.59E-15 - 3.97E-18
1.22E-07 - 4.65E-14
3.21E-07 - 6.85E-14
3.21E-07 - 2.97E-14

No. of
genes
115
90
78
67
62

Figure 5.5. IPA network. The top IPA network (Score = 48) with 26 of the 212
experimentally observed target genes of the 3 miRNAs. The associated network functions
are cell cycle, connective tissue development and function and cancer.
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5.4. Discussion
Increasing numbers of investigators are identifying miRNAs to be involved in
pathologies of several diseases and disorders, including the features of T21
(151,152,160,161). Expression patterns of miRNAs have been studied in the placenta
as well as the chorioamniotic membranes and associations with human pregnancy,
gestational age, and parturition and pregnancy complications (such as preeclampsia
and preterm labor) have been found (65,162–164). MicroRNAs are key regulators of
extracellular matrix (ECM) gene expression and homeostasis, which is perturbed in
preterm premature rupture of membranes (PPROM). Interestingly, the relationship
between miRNAs and ECM is thought to be bi-directional with studies suggesting that
not only can miRNAs regulate ECM composition, but the ECM can also affect miRNA
expression and function (165).
Despite the presence of three chromosomes 21 (a trisomic imbalance), the T21
amniocyte specimens showed reduced expression of the microRNA cluster. This has
been observed by others who quantitated expression of the same microRNAs in other
tissue types and found reduced expression in T21 (152,160). However, other studies
have documented increased expression of these miRNAs in T21 as compared to
euploid controls (151,161,166). These apparent discrepancies could be attributed to
differences in the tissue specimens investigated or differences in normalization
techniques. Reduced expression of the microRNAs in the face of increased gene
dosage may reflect epigenetic changes such as DNA methylation that dampen
expression (167). The reduced expression of the three microRNAs would presumably
increase the expression of the proteins encoded by the target mRNAs. Although all
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three miRNAs are known to be expressed in the placenta and chorioamniotic
membranes, an in-depth expression analysis has not been performed. Prior studies
investigating the roles of these miRNAs in context of other diseases reveal findings
suggesting a true potential for their involvement in fetal membrane pathology. For
example, miR-99a expression has been studied in several cancers and plays crucial
roles in the PI3K/AKT and NF-κB signaling pathways (168,169). In fact, the miR-99a/let7c/miR-125b locus on Chr-21 is phylogenetically conserved, is transcribed as a
polycistronic message, and regulates TGFβ/Wnt signaling pathways in hematopoietic
stem and progenitor cell homeostasis (170). Members of the miR-125 family of miRNAs
are involved in diverse cell functions and have been associated with several diseases.
MiR-125 miRNAs target a range of genes, including transcription factors and matrix
metalloproteinases (MMPs), which are involved in ECM metabolism and also have
important functions in immunological pathways. Another study found that miR-125b is
upregulated in third trimester placentas compared to first trimester placentas,
suggesting it has a role in gestational age (162,171). Let-7 miRNAs are negatively
regulated by the RNA-binding protein, Lin28, and both act downstream of the NF-κB
signaling pathways. Like miR-125b, let-7 miRNAs, including let-7c are upregulated in
third trimester human placentas compared to the first trimester (162). In support of our
results, another study found tissue-specific let-7c expression differences at term, with
significantly reduced expression in choriodecidua as compared to amnion and placenta
(172).
In the current study, in addition to the tissue-specific expression patterns, we also show
differential expression patterns at different locations within the choriodecidua.

105

Differences between the rupture zone and the non-rupture sites are especially
biologically relevant. The rupture site of fetal membranes is characterized by unique
histologic and biochemical changes. These changes are observed even in the portion of
fetal membranes overlying the cervix (thought to be eventual site of spontaneous
rupture) in patients at term without labor. This area is termed as the “zone of altered
morphology” (ZAM) and is characterized by increased thickness of connective tissue
and decreased thickness of cytotrophoblast and decidua (130,173–175). These
changes would require large-scale transcriptional reprogramming, which can be carried
out, at least in part, by miRNA-regulation. Nhan-Chang et al (153) showed gene
expression differences between the amnion and the choriodecidua at both the rupture
as well as non-rupture sites, whereas within each fetal membrane individually, only the
choriodecidua showed gene expression differences between the rupture and nonrupture sites. These results are in accordance with the miRNA expression patterns in
our study, and support the concept that the altered gene expression in fetal membranes
in the rupture zone could be due to altered miRNA expression patterns. It is important
to note that the decreased thickness in the cytotrophoblast and maternal decidual cell
layers at the rupture site in the chorion compared to non-rupture sites (130,173–175)
can influence the observed miRNA expression levels at these sites. Furthermore, the
genes identified by Nhang-Chang et al (such as IL-6, IL1RN, CXCL12, ADAMTS5) were
involved in inflammatory response, immune tolerance pathways as well as ECMreceptor interactions. This suggests that miRNAs from the Chr21orf34 locus could be
involved in regulation of these pathways in the fetal membranes as well, which is quite
plausible considering the evidence for these functional roles is already established in
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other tissues and disease states (165,168–171). In silico pathway analysis of the
experimentally observed gene targets of the three miRNAs revealed an overrepresentation of genes related to cellular growth and proliferation, cell death and cell
survival pathways, all of which are crucial in ECM function during membrane rupture
(176). Notably, the top network based on functional annotation of the genes targeted by
the three miRNAs included COL1A2, which is one of the major fibrillar collagens present
in fetal membranes contributing to the tensile strength of the amnion and associated
with preterm birth (105). The network also included SMAD which suggests involvement
of the TGFβ-Smad signaling pathway which plays a role in ECM metabolism and fetal
membrane rupture via transcription regulation of various collagens, MMPs and tissue
inhibitors of metalloproteinases (TIMPs) (48,177).
In conclusion, we show evidence for distinct tissue and region specific miRNA
expression patterns in fetal membranes from subjects with spontaneous term labor.
These miRNAs are expressed at a reduced level in T21 and this alteration may promote
abnormalities in fetal membranes associated with T21, including chorio-amnion
separation or delayed fusion of the chorion and amnion.
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Chapter 6: Perspectives and Future Directions

Please note:
The section “6.2.1: A hypothetical model for DENND1A and GWAS candidate loci in
PCOS” is adapted from a published journal article
(Jan M. McAllister, Richard S. Legro, Bhavi P. Modi, and Jerome F. Strauss III.
Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends in
Endocrinol Metab, 2015; 26 (3))
The section “6.2.3: Pharmacogenomics in PCOS” is part of a published journal article
(Cindy T. Pau*, Kai I. Cheang*, Bhavi P. Modi, Thushiga Kasippillai, Candace C.
Keefe, Maria Shulleeta, William S. Evans, Lubna Pal, Jerome F. Strauss III, John E.
Nestler, Corrine K Welt. The Role of Variants Regulating Metformin Transport and
Action in Women with Polycystic Ovary Syndrome. (*Authors contributed equally);
Pharmacogenomics 2016; 17 (16))
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6.1. Underlying themes
While all of the projects described in this thesis are more or less distinct, they all are
focused on understanding the genetic and epigenetic differences leading to disease
susceptibility. Each chapter employs a unique data set with the most relevant
approaches used to answer specific questions. Beyond the specific research questions
addressed in each chapter, certain wider themes were apparent across multiple
projects, which pertain to the study of complex genetic studies as a whole. Central to
the study of complex genetic traits is the understanding of gene expression regulation
and function. This is a multistep process that includes defining the genetic architecture,
identifying genes and variants within these genes associated with disease risk and
translating these associations into disease mechanisms. As explained in the
introduction, the chapters in this thesis take different approaches towards reaching this
goal in the context of two complex reproductive disorders – PCOS and PPROM.
Chapter 2 describes the investigation of different possible genetic mechanisms for V2
overexpression in PCOS and the negative results obtained indicate either we do not
have sufficient data to clearly elucidate a genetic mechanism (owing to small sample
size) or that epigenetic mechanisms may play a role and the results in Chapter 3
support our hypothesis by showing evidence for potential miRNA regulation of the
DENND1A gene. In addition, it is important to note other epigenetic mechanisms
including DNA methylation and histone modifications may be involved and need to be
studied. In addition, Chapter 4 describes an approach to identify low frequency rare
variants that contribute to PPROM risk susceptibility in select candidate genes by
integrating bioinformatics and known disease pathology (discussed below).
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One additional theme is the role of miRNAs contributing to the epigenetic mechanisms
of complex disorders as discussed in Chapters 3 and 5. While DNA methylation and
histone modifications are usually investigated in lieu of epigenetic regulation of gene
expression, miRNAs also contribute to this landscape of gene expression regulation by
post-transcriptional translational inhibition or mRNA degradation with no changes to the
underlying DNA sequence. Differential miRNA expression patterns have contributed to
several disease mechanisms including cancer, neurological disorders, cardiovascular
diseases, diabetes etc. Chapter 3 shows evidence for differential expression for two
different miRNAs in PCOS theca cells. In addition, differential expression was correlated
to increased androgen (DHEA) production – which is a measure of the
hyperandrogenism associated with PCOS. In addition, Chapter 5 describes tissue and
location specific expression patterns of Chr-21 derived miRNAs in the chorioamniotic
membranes in term pregnancies with spontaneous rupture. The results suggest a
unique expression pattern in rupture site of the chorion, supporting our hypothesis that
gene expression changes at the rupture site leading to membrane rupture at term could
be regulated by miRNAs. This pilot study provides support for a detailed miRNA
expression analysis in fetal membranes from term pregnancies with and without
membrane rupture and pregnancies complicated by PPROM.
In addition, utilization of in silico network analysis in Chapters 3 and 5 really underlines
the overall scope of this thesis by giving preliminary evidence for a common network of
miRNAs (epigenetic) and genes (genetic) implicated either a priori (by association
studies) or via validated and/ or predicted miRNA-gene interactions being involved in
complex disease susceptibility.
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Another common theme is integration of biological theory and standard next-generation
genetic analysis techniques to make the studies more functionally informative.
Identification of risk loci will have applicable value only when risk loci can improve our
understanding of disease pathophysiology and in the long-term impact healthcare
management and a “hypothesis-driven” approach can aid in designing studies that are
better equipped in this direction. This was particularly helpful in Chapter 4 where
knowledge of biological function of genes and association to biological etiology of
disease allowed us to focus on a manageable number of candidate genes and variants
there in from a large data set obtained from Whole Exome Sequencing. In addition, prior
studies on biological relevance of DENND1A in PCOS directed the mechanistic and
functional aspects of Chapters 2 and 3. Moreover, Chapter 5 integrates epidemiological
evidence of fetal membrane abnormalities in Trisomy 21 and contribution of Chr-21
miRNAs to T21 phenotypes leading to the study of location and tissue specific
expression patterns of Chr-21 miRNAs in chorioamniotic membranes.
The results obtained in each separate project reinforce the notion that both genetic and
epigenetic mechanisms and their complex interactions need to be studied in detail to
understand the complex traits. As discussed in the introduction, several of these
mechanisms are even more challenging to study for complex reproductive traits and
adverse pregnancy outcomes such as PCOS and PPROM respectively. This thesis is
an example of how a better understanding of these concepts can be achieved by
defining specific research questions and identifying the best methods to address those
questions effectively. In addition, several of these studies have led to potential future
directions that will add more clarity towards the genetic and epigenetic mechanisms in
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complex reproductive disorders. The rest of the chapter entails brief descriptions of
these future projects some of which are already in progress.

6.2 Future Directions
6.2.1. A hypothetical model for DENND1A and other GWAS candidate loci in
PCOS
A previous study has described the role of increased expression of a DENND1A isoform
- V2 contributing to PCOS pathophysiology via steroidogenic regulation in PCOS theca
cells (70), however the precise etiology by which V2 alters theca cell function is not
known. However, the structural features of the V2 protein and its cytoplasmic and
nuclear location in theca cells described previously (70) provide important clues for
speculating a possible molecular model for its function, perhaps in conjunction with
other GWAS candidate loci (Figure 6.1.). V2 could be involved in modification of
gonadotropins (FSHR, LHCGR) and INSR (all three are known GWAS candidate loci)
signal transduction cascades via receptor-mediated recycling/ endocytosis through
clathrin-coated vesicles by interactions via the clathrin-binding domain in the V2
structure. In addition, DENND1A functions as a Rab-specific guanine nucleotide
exchange factor (GEF) that interacts with Rab-specific GTPases such as RAB5B (also a
GWAS candidate gene) and are involved in endocytic processes. V2 could influence
gene transcription of androgen producing genes by transport of ligand (FSH, LH, INS)
and/ or receptor (FHSR, LHCGR, INSR) into the nucleus via these processes.
Alternatively, V2 localized in the nucleus could be a scaffold for transcription factors
some of which are GWAS genes including TOX3, YAP1, HMGA2 and ZNF217 or others
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such as GATA family of transcription factors which ultimately regulate steroidogenic
enzyme gene expression. These transcription factors can act independently of V2 to
influence gene expression as well. Preliminary evidence (not shown) indicates V2mediated activation and regulation of PI3K/MAPK pathways, which could then regulate
several other downstream signaling cascades leading to transcriptional regulation of
gene expression contributing to the PCOS phenotype. Detailed molecular studies
designed to clearly define and outline these hypothesized interactions need to be
performed.
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Figure. 6.1. A hypothetical model for DENND1A and other GWAS candidate loci in
PCOS. The different possible mechanisms by which DENND1A and other GWAS
candidate loci (shown in brown boxes) can contribute to the steroidogenic phenotype of
PCOS theca cells is shown. The different mechanisms (described in detail in section
6.2.1) include gene transcription regulation via DENND1A mediated endocytosis of
ligand/ receptor via clathrin-coated vesicles without or in conjunction with RAB5B and
gene expression regulation via transcription factors dependent or independent of
nuclear V2.
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6.2.2. A transgenic mouse model for PCOS
The existing PCOS animal models are based on treatment of the animals with
androgens, or prenatal exposure to androgens in utero (178,179). However, a mouse
model created following a gene-based approach is lacking. Based on our studies with
DENND1A in theca cells (70), it was hypothesized that global overexpression of human
DENND1A.V2 in a transgenic mouse should reproduce the PCOS phenotype (at least
the steroidogenic phenotype). In addition, this provides an opportunity to study the
pathophysiological role of V2 in PCOS in vivo. A C57BL6 background was used to
create three transgenic lines overexpressing V2 using the construct shown in Figure
6.2.
While transgene expression at the mRNA level was detectable in two of the three
transgenic lines, establishing transgene protein expression was inconsistent and
difficult. Fertility and fecundity did not appear to be different between wildtype (WT) and
transgenic (Tg) animals. Steroidogenic phenotypes of increased plasma DHEA,
androstenedione, progesterone and testorone levels were observed in Tg animals
compared to WT. Unlike humans, mouse adrenal glands do not synthesize androgen
(180). However, Cyp17 gene expression (mRNA and protein) was detected in the
adrenal glands of Tg animals overexpressing V2, whereas, no expression was detected
in the WT animals. Adrenal androgen production needs to be further confirmed by
cortisol assays.
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Figure 6.2. DENND1A.V2 construct. pCMV-BAM vector containing the human
DENND1A.V2 cDNA under control of the CMV promoter, as well as rabbit β-globin
sequences that provide an intron for efficient transgene expression and a
polyadynelation site. This construct was used to create three transgenic lines on a
C57BL/6 background.
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6.2.2. Rare variant analysis in negative regulators of the immune response
contributing to PPROM.
As described in Chapter 4, identification of low-frequency rare variants in the fetal
genome is an approach towards identification of genetic variants contributing to disease
susceptibility in PPROM that has not been used. As Chapter 4 focused on damaging
variants in fibrillar collagen genes contributing to ECM structure and metabolism, using
a similar approach, future studies will focus on identification of rare variants in fetal
genes involved in the suppression of the inflammatory response triggering matrix
degradation.
Chorioamnionitis (inflammation of fetal membranes) and/ or unchecked innate immune
response resulting from bacterial infection are major risk factors associated to PPROM
(181–183). Gene expression differences of key mediators of inflammation and innate
immune response pathways in fetal membranes of normal term pregnancies and
PPROM patients have been identified. Negative regulators on innate immune signaling
help to keep inflammation in check. Host genetic factors significantly contribute to interindividual variation in susceptibility to infection and severity on innate immune response.
Identification of damaging variants that potentially disrupt expression and/ or function of
genes involved in negative regulation of inflammation and the innate immune response
may lead to identification of genetic predictors of PPROM. Using this rational and the
same methodology described in Chapter 4, the candidate genes interrogated included
anti-inflammatory cytokines such (IL10, IL10RA, IL10RB), suppressors of cytokine
signaling (SOCS1, SOCS2, SOCS3), intracellular mediators (CARD6, CARD8, NOD2,
NFKBIE) and pattern recognition receptors (NLRP3, NLRP10, NLRP12, TLR10).
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Of particular note were the mutations/potentially damaging variants in NFKBIE, an
inhibitor of the NFkB activation (Appendix Table A.6.1). In addition, predicted to be
damaging missense variants were found only in PPROM cases in NLRP10, a negative
regulator of the innate immune inflammasome pathway and NOD2, an intracellular
protein in the NFkB pathway. A frameshift mutation rs2066847 was identified in the
NOD2 gene with allele frequency of 0.0042 in all PPROM cases combined (49 cases
used in WES and 188 cases used for the follow-up genotyping). A nonsense mutation,
rs765522475, was identified in the NLRP10 gene with an allele frequency of 0.0021 in
all PPROM cases combined. Detailed analysis of these variants in association to
PPROM is warranted.
6.2.3. Pharmacogenomics in PCOS
As mentioned earlier, true value of identification of genetic variants impacting disease
susceptibility lies in their applications towards understanding disease pathophysiology
and contribution towards healthcare. Pharmacogenomics, which is the study of how
genes and genetic variants affect a person’s response to drugs, is now being
increasingly applied to the study of complex genetic disorders as well. In an attempt to
study the application of pharmacogenomics in PCOS, a small project to understand the
role of variants regulating metformin transport and action in women with Polycystic
Ovary Syndrome was performed. The study was a collaborative effort and has been
published in Pharmacogenomics (184). A brief description of study design and key
findings for the work performed at Virginia Commonwealth University are described
below.
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Metformin is widely used to treat women with PCOS based on the concept that it
improves insulin resistance. However, reports have demonstrated that metformin does
not improve insulin resistance, rather it improves fasting glucose levels and glucose
effectiveness in women with PCOS. In addition, other reports indicate that metformin
lowers testosterone levels and increases ovulation rates in a subset of women with
PCOS independent of insulin action (185–189). Thus, the mechanism of metformin
action in PCOS remains unclear and identifying the subset of patients who will benefit
from metformin remains a challenge. Metformin is transported into hepatocytes by
organic cation transporter 1 (OCT1 or SLC22A1), out of hepatocytes and renal tubular
epithelium by multidrug and toxin extrusion 1 (MATE1 or SLC47A1), and eliminated
through the renal tubule cells by organic cation transporter 2 (OCT2 or SLC22A2). All
three transporters are expressed in the ovaries, hepatocytes and skeletal muscle and
genetic variants in these genes have been demonstrated to affect metformin transport
response in patients with type 2 diabetes. In addition to metformin transport protein
heterogeneity, a variant in linkage disequilibrium with the ataxia-telangiectasia mutated
gene (ATM; rs11212617) has been associated with reduced HbA1C levels after
metformin treatment through phosphorylation and activation of the AMPK pathway
(190–194). This suggested that the genetic variability in metformin transporters and
mediators may affect metformin levels and action in relevant tissues in women with
PCOS and have clinical significance.
Genotyping for loss of function variants (associated with protein change) in SLC22A1,
SLC22A2, SLC47A1 and ATM was performed on genomic DNA isolated from women
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with PCOS (n = 26). (Details regarding the other cohorts, clinical criteria and metformin
dosage used can be found in the full version of the paper (184)).
Briefly, the study failed to demonstrate a relationship between metformin transporter
variants and glucose, insulin and testosterone levels, a response to an oral glucose
tolerance test, and ovulation in patients with PCOS. Thus, the data from the current
study does not support an important effect of these variants in the response to
metformin in PCOS.
However, it is important to note the heterogeneity in the different sample cohorts used in
the study – including the strength and duration of metformin treatment, which can mask
true effects. This highlights the need for replication studies with increased sample sizes
and uniform study design.
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Table A.3.1. Specific theca cell cultures used for miRNA sequencing and qPCR
assays in Chapter 3 (miRNA and gene qPCRs). C and F indicate control
(untreated) and forskolin treated samples

Sample ID

Category

Included in
MiRNA
Sequencing

MC02_C/F

Normal

Yes

No

MC06_C/F

Normal

Yes

Yes

MC31_C/F

Normal

Yes

Yes

MC38_C/F

Normal

No

Yes

MC40_C/F

Normal

Yes

Yes

MC50_C/F

Normal

Yes

Yes

MC10_C/F

PCOS

Yes

Yes

MC16_C/F

PCOS

Yes

Yes

MC27_C/F

PCOS

Yes

Yes

MC190_C/F

PCOS

Yes

Yes
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Included in
QPCR assays

Figure. A.4.1. COL2A1 mRNA expression in amnion samples from normal term
pregnancies.
RT-PCR gel picture for COL2A1 (1371 bp) using 1 µg RNA from amnion tissue samples
obtained from normal term pregnancies (lanes 1-6) showing mRNA expression of the
COL2A1 gene in the amnion.
(COL2A1 Primers: 5-CAAGGCCCCAGAGGTGACA-3 and
5-AGGCGGACATGTCGATGCCA-3)
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Table A.4.1.A. Comparison of neonatal ancestry between cases and controls in
the initial WES:
Neonatal case (n = 49) and control (n = 20) samples were compared for European and
West-African ancestry proportions. Values represent mean genetic ancestry estimates
generated using two-way model of admixture following maximum likelihood method with
SD in parentheses.
Cases

Control

Ancestry
European
West-African

p-value
Mean (SD)

Mean (SD)

0.295 (0.070)

0.314 (0.107)

0.705 (0.070)

0.685 (0.107)

0.463
0.463

Table A.4.1.B Comparison of neonatal ancestry between cases and controls in the
follow-up genotyping study.
Neonatal case (n = 188) and control (n = 175) samples were compared for European
and West-African ancestry proportions. Values represent mean genetic ancestry
estimates generated using two-way model of admixture following maximum likelihood
method with SD in parentheses.
Cases

Control

Mean (SD)

Mean (SD)

0.1823 (0.083)

0.1658 (0.119)

0.134

0.8341 (0.119)

0.134

Ancestry
European
West-African

p-value

0.8176 (0.083)
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Table A.4.2. Missense variants not selected.
Missense variants identified by WES in the genes of interest but not selected for
analysis in this study are listed along with their SIFT and Polyphen2 predictions and the
observed putative risk allele frequencies (RAF) for cases (n = 49) and controls (n = 20).
Novel variants were submitted to dbSNP and ss ids are provided. In cases of multiple
SIFT and PolyPhen2 predictions for variants that were annotated to multiple isoforms,
only distinct predictions are listed (i.e. does not reflect the total number of isoforms that
were actually annotated). (SIFT predictions: T = Tolerated, D = Damaging; Polyphen2
predictions: B = Benign, P = Possibly Damaging, D = Probably Damaging).
PolyPhen
Allele
Gene

SNP ID

SIFT

Location

RAF

RAF

Cases

Controls

2_HDIV
Change prediction
prediction

chr17:
COL1A1

rs142570406

G>C

T

B

0.01

0

C>T

T

B

0.01

0.025

T>C

T

B

0.93

1

C>T

T

B

0

0.025

C>T

T

P,P

0

0.025

C>G

T

B

0.91

0.85

48264244
chr17:
COL1A1

rs116794104
48272827
chr17:

COL1A1

rs1800215
48265495
chr17:

COL1A1

rs145446512
48266851
ss20194925

chr7:

54

94029523

rs42524

chr7:

COL1A2
COL1A2
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94043239
chr7:
COL1A2

rs150124840

C>T

T

P

0.01

0

G>A

T

P

0

0.025

G>A

T

B,B

0

0.025

T>A

T

B,B

0.56

0.575

T>A

T

B,B

0.01

0.025

C>T

T

B,B

0.03

0

C>T

T

D,D

0.05

0.075

G>A

T

B,B

0.03

0

G>A

T

D

0

0.025

C>T

T

D

1

0

G>A

T

B

0.1

0.1

94057691
chr7:
COL1A2

rs35820023
94056353
chr12:

COL2A1

rs140368756
48372444
chr12:

COL2A1

rs3803183
48398080
chr12:

COL2A1

rs34392760
48391657
chr12:

COL2A1

rs12721427
48368541
chr12:

COL2A1

rs2070739
48367976
chr12:

COL2A1

rs201823490
48380213
chr2:

COL3A1

rs201220788
189870163
chr2:

COL3A1

rs373838193
189862102
chr2:

COL3A1

rs1800255
189864080
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chr2:
COL3A1

rs1801183

C>T

T

P

0.01

0

C>G

T

B

0.01

0

T>G

T

B

1

1

C>G

D

P

0.01

0

G>A

T

D

0

0.025

G>A

T

B

0.01

0

G>A

T

D

0.01

0

A>T

T

B

0

0.025

A>G

N/A

B,P

0.01

0

C>G

N/A

B

0.01

0.025

A>C

T,T

P

0.01

0

G>C

T

D

0.01

0

189863424
chr2:
COL3A1

rs41263775
189864044
chr2:

COL3A1

rs1516446
189875421
chr9:

COL5A1

rs147008954
137593122
ss20194925

chr9:

56

137698068

COL5A1
chr9:
COL5A1

rs61729495
137734039
chr9:

COL5A1

rs61735045
137642654
ss20194925

chr9:

COL5A1
55

137620639
chr2:

COL5A2

rs35852101
189931144
chr2:

COL5A2

rs6434313
189916110
chr3:

CRTAP

rs145623565
33161975

CRTAP

ss20194925

chr3:

157

50

33155942

ss20194925

chr7:

53

73474329

ELN

G>T

T

B

0.01

0

G>A

T

B

0.21

0.25

G>T

T

D

0.02

0.05

C>T

T

B

0.01

0

G>T

T

P

0.01

0

G>A

T

D

0.01

0.025

G>A

T

D,P

0.01

0

G>T

T

D

0.01

0

A>G

T

P

0

0.05

C>G

T

P

0.03

0.025

C>T

T

B

0

0.05

chr7:
ELN

rs2071307
73470714
chr7:

ELN

rs61734581
73459575
chr7:

ELN

rs144026807
73474485
chr7:

ELN

rs137987089
73474484
chr7:

ELN

rs140425210
73477524
ss20194925

chr7:

52

73457326

ELN
chr7:
ELN

rs145612009
73462008
chr7:

ELN

rs34945509
73472000
chr7:

ELN

rs144341345
73470729

ADAMTS

chr5:
rs35445112

2

178555097

158

ADAMTS

chr5:
rs398829

2

178634672

ADAMTS

chr5:
rs59567206

2

178634704

ADAMTS

chr5:
rs11750821

2

178634683

ADAMTS

chr5:
rs143764421

2

178634657

ADAMTS

chr5:
rs35372714

2

178563002

ADAMTS

chr5:
rs1054480

2

178540975

ADAMTS

chr5:
rs79330641

2
ADAMTS

ss20194925

B

0.43

0.525

T>C

T

B

0.08

0.075

C>T

T

B

0.01

0.075

C>T

T

B

0

0.025

C>T

T

B

0

0.025

G>A

T

P

0.07

0.1

G>A

T

B

0.02

0.05

C>T

T

D,P

0.01

0

G>C

T

P

0

0.025

C>A

T

B

0

0.025

A>G

D

B,P

0.01

0

A>G

T

B

0.12

0.1

chr5:

51

178771124

SERPIN

ss20194925

chr11:

57

SERPIN

75277973
chr11:

rs141721173
H1

75277974

SERPIN

chr11:
rs138784081

H1
FKBP10

T

178549719

2

H1

C>T

75277959
rs34764749

chr17:

159

39974642
chr17:
FKBP10

rs76022961

G>A

T

P,B

0.02

0.05

G>A

D

B

0.01

0

A>G

T

D

0.01

0

39978052
chr17:
FKBP10

rs201944190
39978604
chr17:3996

FKBP10

rs145424241
9495
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Table A.5.1. Fetal gender comparison for hsa-let-7c.
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered
significant (bold)).
Location/Tissue

mean Female

mean Male

p-value

MRA

1.490

0.622

0.12032

MRC

0.857

-0.310

0.00095

PPA

1.443

0.983

0.57719

PPC

0.614

0.176

0.36579

RZA

1.178

0.373

0.15320

RZC

-0.273

-1.468

0.09397

Table A.5.2. Fetal gender comparison for hsa-miR-125b.
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered
significant (bold)).
Location/Tissue

mean Female

mean Male

p-value

MRA

-6.212

-6.202

0.991

MRC

-6.137

-6.624

0.483

PPA

-5.401

-5.667

0.777

PPC

-6.408

-6.184

0.624

RZA

-6.583

-5.859

0.502

RZC

-7.179

-7.056

0.870
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Table A.5.3. Fetal gender comparison for hsa-miR-99a.
Comparisons of log2 expression of hsa-let-7c at the 6 different sampling sites with
respect to male vs. female fetal gender are shown. (P < 0.0071 was considered
significant (bold)).
Location/Tissue

mean Female

mean Male

p-value

MRA

1.689

1.323

0.579

MRC

0.351

-0.015

0.291

PPA

1.712

1.514

0.706

PPC

0.165

0.154

0.970

RZA

1.221

1.369

0.824

RZC

-0.397

-0.483

0.792
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Table A.6.1. NFKBIE variants identified in WES and unique to cases.

Alternate
Chromosome 6
SNP

Reference

Alternate

Allele

Allele

Type
Location

allele
frequency

rs10081001
rs12211448
rs2233429
rs2233437
rs28362860
rs369182955
rs372668192
rs79985077

44227330
44227751
44233488
44228162
44227224
44232670
44232707
44230663

Intron

G

A

0.09

Intron

C

A

0.04

missense

T

A

0.01

Intron

G

A

0.17

Intron

C

T

0.04

Intron

G

A

0.01

Intron

C

T

0.01

Intron

C

T

0.01

163

Vita

Bhavi Pinesh Modi was born on January 6, 1989 in Mumbai, India. She graduated from
the University of Mumbai with a Bachelor’s (2010) and a Master’s (2012) degree in
Biotechnology. She gained experience in reproductive biology while working on her
Master’s dissertation thesis entitled “Receptor for Advanced Glycation End Products
(RAGE): Effect of AGEs, Glucose and Hormone Stimulation in Endometrial Cells” at the
National Institute for Research in Reproductive Health. She then moved to the United
States to pursue a Ph.D. in Human Genetics and continued her passion for reproductive
research in Dr. Jerome F. Strauss’s laboratory. Under the guidance of Dr. Strauss, she
completed her Ph.D. dissertation entitled “Genetic and epigenetic mechanisms of
complex reproductive disorders.” During her graduate training, she became well versed
in several genomic and bioinformatics analysis techniques, miRNA regulation and
application of these techniques towards understanding and identification of risk factors
contributing to disease susceptibility. She received the C. C. Clayton Award from
Virginia Commonwealth University in March, 2016 and was inducted into the Phi Kappa
Phi Honor Society in November, 2016. She has presented her research at international
conferences for the Society of Reproductive Investigation in 2015 and 2016 and has
published several peer-reviewed journal articles as well as a book chapter.

164

165

